LLISTA DE LES PRINCIPALS PUBLICACIONS
Revisi l'abstract o sol.liciti una còpia de l'article (format PDF).

Data	Publicación
2009	AIDS PATIENT CARE and STDs
Carmina R. Fumaz, Ph.D., Jose A. Muñoz-Moreno, M.S., María José Ferrer, M.S., Eugenia Negredo, Ph.D., Nuria Pérez-Álvarez, M.S., Antoni Tarrats, Ph.D., and Bonaventura Clotet, Ph.D.  Low Levels of Adherence to Antiretroviral Therapy in HIV-1–Infected Women with Menstrual Disorders
2009	AIDS Res Hum Retroviruses
E. Negredo, J. Puig, D. Aldea, M. Medina, C. Estany, N. Pérez-Alvarez, CR. Fumaz, J. Muñoz-Moreno, C. Higueras, V. Gonzalez-Mestre, B. Clotet  Four-year safety with polyacrylamide hydrogel to correct antiretroviral-related facial lipoatrophy
2009	CID
Athe M. N. Tsibris, Roger Paredes, Amy Chadburn, Zhaohui Su, Timothy J. Henrich, Amy Krambrink, Michael D. Hughes, Judith A. Aberg, Judith S. Currier, Karen Tashima, Catherine Godfrey, Wayne Greaves, Charles Flexner, Paul R. Skolnik, Timothy J. Wilkin, Roy M. Gulick and Daniel R. Kuritzkes  Lymphoma Diagnosis and Plasma Epstein-Barr Virus Load during Vicriviroc Therapy: Results of the AIDS Clinical Trials Group A5211
2009	Current HIV Research
JM Llibre  The Changing Face of HIV/AIDS in Treated Patients
2009	HIV Clinical Trials
José Ramon Santos, José Moltó, Josep Maria Llibre, Núria Pérez, Mari Carmen Capitán, Cristina Miranda, Bonaventura Clotet  Unboosted Atazanavir Plus co-formulated Lamivudine/Abacavir as a Ritonavir-Sparing Simplification Strategy in Routine Clinical Practice
2009	HIV Clinical Trials
José Ramón Santos, José Moltó, Josep Maria Llibre, Nuria Pérez, Mari Carmen Capitán, Cristina Miranda and Bonaventura Clotet  Unboosted Atazanavir Plus Co-formulated Lamivudine/Abacavir as a Ritonavir-Sparing Simplification Strategy in Routine Clinical Practice
2009	Journal of Antimicrobial Chemotherapy
José Moltó, Josep Maria Llibre, Esteban Ribera, Carlos Mínguez, Jesús Sánchez del Río, Enric Pedrol, Gabriel Vallecillo, Samandhy Cedeño, Marta Valle, Cristina Miranda, Eugenia Negredo and Bonaventura Clotet on behalf of the SQV-HEP Study Group.  Saquinavir exposure in HIV-infected patients with chronic viral hepatitis
2009	Journal of Virology
Roger Paredes, Manish Sagar, Vincent C. Marconi, Rebecca Hoh, Jeffrey N. Martin, Neil T. Parkin, Christos J. Petropoulos, Steven G. Deeks, and Daniel R. Kuritzkes  In Vivo Fitness Cost of the M184V Mutation in Multidrug-Resistant Human Inmunodeficiency virus Type 1 in the Absence of Lamiduvine
2008
Jose Molto, Marta Valle, Cristina Miranda, Samandhy Cedeno, Jose Miranda, Jose Ramon Santos, Eugenia Negredo, Josep Vilaro, Joan Costa, Bonaventura Clotet   Once or Twice Daily Dosing of Nevirapine in HIV-Infected Adults: A Population Pharmacokinetics Approach
2008	AIDS Care, Vol. 20, No. 7, August 2008, 796 - 805.
Fumaz CR, Muñoz-Moreno JA, Moltó J, Ferrer MJ, López-Blázquez R, Negredo E, Paredes R, Gómez G, Clotet B.  Sustained antiretroviral treatment adherence in survivors of the pre-HAART era: attitudes and beliefs. AIDS Care 2008;20(7):796-805.
2008	AIDS RESEARCH AND HUMAN RETROVIRUSES Volum 24, Número 10, 2008
Jose A. Muñoz-Moreno, Carmina R. Fumaz, Maria J. Ferrer, Anna Prats, Eugènia Negredo, Maite Garolera, Núria Pérez-Álvarez, José Moltó, Guadalupe Gómez i Bonaventura Clotet  Nadir CD4 Cell Count Predicts Neurocognitive Impairment in HIV-Infected Patients
2008	AIDS RESEARCH AND HUMAN RETROVIRUSES, Volume 24, Number 5, 2008
Laila Darwich, Anna Esteve, Lídia Ruiz, Roger Paredes, Rocío Bellido, Cecília Cabrera, Joan Romeu, Margarita Bofill, Bonaventura Clotet, and Javier Martínez-Picado  Drug-Resistance Mutations Number and K70R or T215Y/F Substitutions Predict Treatment Resumption during Guided Treatment Interruptions
2008	ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Nov. 2008
José Moltó, José R. Santos, Núria Pérez-Álvarez, Samandhy Cedeño, Cristina Miranda, Saye Khoo, Laura Else, Josep Maria Llibre, Marta Valle and Bonaventura Clotet  Darunavir Inhibitory Quotient Predicts the 48-Week Virological Response to Darunavir-Based Salvage Therapy in Human Immunodeficiency Virus-Infected Protease Inhibitor-Experienced Patients
2008	Clinical Pharmacokinetics
José Moltó, Manuel José Barbanoj, Cristina Miranda, Asunción Blanco, José Ramón Santos, Eugenia Negredo, Joan Costa, Pere Domingo, Bonaventura Clotet, Marta Valle  Simultaneous Population Pharmacokinetic Model for Lopinavir and Ritonavir in HIV-Infected Adults
2008	Enferm Infecc Microbiol Clin. 2008;26 Supl 12:17-22
Josep M. Llibre y Javier Martínez-Picado  Potencial de los inhibidores de la integrasa para deplecionar los reservorios o para impedir que se rellenen
2008	HIV Medicine
JM Llibre, A Bonjoch, J Iribarren, MJ Galindo, E Negredo, P Domingo, N Pérez-Álvarez, J Martínez-Picado, J Schapiro, B Clotet and the HIV Conference Call study group  Targeting only reverse transcriptase with zidovudine/lamivudine/abacavir plus tenofovir in HIV-1-infected patients with multidrug-resistant virus: a multicentre pilot study
2008	JAIDS (J Acquir Immune Defic Syndr)
Vincent Marconi, MD, Sebastian Bonhoeffer, PhD, Roger Paredes, MD, Jing Lu, MD, Rebecca Hoh, RD, Jeffery N. Martin, MPH, Steven G. Deeks, MD and Daniel R. Kuritzkes, MD  Viral Dynamics and In Vivo Fitness of HIV-1 in the Presence and Absence of Enfuvirtide
2008	Journal of Antimicrobial Chemotherapy
J. M. Llibre, J. R. Santos, T. Puig, J. Moltó, L. Ruiz, R. Paredes and B. Clotet  Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz
2008	Journal of Antimicrobial Chemotherapy
Josep M. Llibre, Pere Domingo, Miguel A. del Pozo, Celia Miralles, Maria J. Galindo, Isabel Viciana, Santiago Moreno, Jonathan M. Schapiro and Bonaventura Clotet  Long-distance interactive expert advice in highly treatment-experienced HIV-infected patients
2008	JVI
Roger Paredes, Manish Sagar, Vincent C. Marconi, Rebecca Hoh, Jeffrey N. Martin, Neil T. Parkin, Christos J. Petropoulos, Steven G. Deeks, Daniel R. Kuritzkes  In Vivo Fitness Cost of the M184V Mutation in Multidrug-Resistant HIV-1 in the Absence of Lamivudine
2007	AIDS care; 19 (1): 138-145. (IF: 2.093).
Fumaz, CR.; Munoz-Moreno, JA.; Ballesteros, AL.; Paredes, R.; Ferrer, MJ.; Salas, A.; Fuster, D.; Masmitja, E.; Perez-Alvarez, N.; Gomez, G.; Tural, C.; Clotet, B.  Influence of the type of pegylated interferon on the onset of depressive and neuropsichiatric symptoms in HIV-HCV coinfected patients.
2007	AIDS Cyber J; 10 (6).
Muñoz-Moreno, JA.  Alteraciones neurocognitivas asociadas a las interrupciones del tratamiento antiretroviral en la infección por el VIH.
2007	AIDS Patient Care STDS; 21 (8): 533-543. (IF: 2.007)
Reynes, J.; Arasteh, K.; Clotet, B.; Cohen, C.; Cooper, D.; Delfraissy, JF.; Eron, JJ.; Henry, K.; Katlama, C.; Kuritzkes, DR.; Lalezari, JP.; Lange, J.; Lazzarin, A.; Montaner, JS.; Nelson, M.; Stellbrink, HJ.; Trottier, B.; Walmsley, SL:; Buss, NE.; Demasi, R.; Chung, J.; Donatacci, L.; Guimaraes, D.; Rowell, L.; Valentine, A.; Wilkinson, M.; Salgo, MP.  TORO: Ninety-Six-Week virologic and immunologic response and safety evaluation of Enfuvirtide with optimized background of antiretrovirals.
2007	AIDS Res Hum Retroviruses; 23 (10): 1166-1175.
Muñoz-Moreno, JA.; Fumaz, CR.; Ferrer, MJ.; Tuldrà, A.; Rovira, T.; Viladrich, C.; Bayés, R.; Burger, DM.; Negredo, E.; Clotet, B.; SERAD Validation Team.  Assessing self-reported adherence to HIV therapy by questionnaire: the SERAD (Self-reported adherence) Study.
2007	AIDS Research and Human Retroviruses; 23 (8): 961-967. (IF: 2.513)
Sirera, G.; Videla, S.; Lopez-Blazquez, R.; Llatjos, M.; Tarrats, A.; Castella, E.; Grane, N.; Alcalde, C.; Tural, C.; Rey-Joly, C.; Clotet, B.  Evolution of cervical cytologic changes among hiv-infected women with normal cytology in the HAART era.
2007	AIDS. 21(2):169-178
Ruiz L, Paredes R, Gomez G, Romeu J, Domingo P, Perez-Alvarez N, Tambussi G, Llibre JM, Martinez-Picado J, Vidal F, Fumaz CR, Clotet B; The TIBET Study Group.   Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients.
2007	AIDS: 21 (6): 721-732. (IF: 5.632)
Cozzi-Lepri, A.; Philips, AN.; Ruiz, L.; Clotet, B.; Loveday, C.; Kjaer, J.; Mens, H.; Clumeck, N.; Viksna, L.; Antunes, F.; Machala, L.; Lundgren, JD.  Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
2007	AIDS; 21 (10): 1273-1281. (IF: 5.632)
Nelson, MR.; Katlama, C.; Montaner, JS.; Cooper, DA.; Gazzard, B.; Clotet, B.; Lazzarin, A.; Schewe, K.; Lange, J.; Wyatt, C.; Curtis, S.; Chen, S.; Smith, S.; Bischofberger, S.; Rooney, JF.  The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.
2007	AIDS; 21 (12): 1555-1559. (IF: 5.632)
Dore, GJ.; Torriani, FJ.; Rodriguez-Torres, M.; Bräu, N.; Sulkowski, M.; Lamoglia, RS.; Tural, C.; Clumeck, N.; Nelson, MR.; Mendes-Correa, MC.; Codofsky, EW.; Dieterich, DT.; Yetzer, E.; Lissen, E.; Cooper, DA.  Baseline factors prognostic od sustained virological response in patients with HIV-hepatitis C virus c-infection.
2007	AIDS; 21 (3): 367-369 (IF: 5.632)
Martinez, E.; Arnaiz, JA.; Podzamczer, D.; Dalmau, D.; Ribera, E.; Domingo, P.; Knobel, H.; Leyes, M.; Pedrol, E.; Force, L.; de Lazzari, E.; Gatell, JM. for the NEFA Study Team. Participating centre and investigator: Llibre, JM.  Three-year Follow-up of protease inhibitor-based regimen simplification in HIV-infected patients.
2007	AIDS; 21 (6): 657-663. (IF: 5.632)
Negredo, E.; Estany, C.; Martínez, E.; Clotet, B.  Therapeutic Management of Bone Demineralisation in the HIV-infected population.
2007	AIDS; 21 (6): 657-663. (IF: 5.632)
Negredo, E.; Martínez, E.; Cinquegrana, D.; Estany, C.; Clotet, B.  Therapeutic management of bone demineralization in the HIV-infected population.
2007	Ann Intern Med; 146: 574-579.
Gavalda, J.; Len, O.; Miró, JM.; Muñoz, P.; Montejo, M.; Alarcón, A.; de la Torre-Cisneros, J.; Peña, C.; Martinez-la Casa, X.; Sarria, C.; Bou, G.; Aguado, JM.; Navas, E.; Romeu, J.; Marco, F.; Torres, C.; Tornos, P.; Planes, A.; Falcó, V.; Almirante, B.; Pahissa, A.  Treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone.
2007	Antiviral Therapy (en prensa)
Negredo, E. et al.  Partial immunological and mithocondrial recovery after reducing Didanosine doses in patients receiving Didanosine and Tenofovir-Based regimens.
2007	Antiviral Therapy; 12: S680. (IF: 4.98)
Llibre, JM.; Bonjoch, A.; Iribarren, JA.; Galindo, MJ.; Martinez-Picado, X.; Arazo, P.; Santos, JR.; Domingo, P.; Clotet, B.  Viral evolution in HIV-1 reverse transcriptase in patients receiving a holding regimen with Trizivir and tenofovir with persistent viral replication.
2007	Antiviral Therapy; 12: S74. (IF: 4.98)
Llibre, JM.; Santos, JR.; Puig, T.; Moltó, J.; Ruiz, L.; Clotet, B.  Prevalence of etravirine-associated mutations in clinical samples with resistance to nevirapine and efavirenz.
2007	Area clínica; 15 (57): 83-93
Clotet, B.  Revisión clínica de Raltegravir (MK-0518). El primero en una nueva clase terapéutica para VIH.
2007	Br J Clin Pharmacol; 63 (6): 715-721. (IF: 2.718)
Molto, J.; Blanco, A.; Miranda, C.; Miranda, J.; Puig, J.; Valle, M.; Delavarga, M.; Fumaz, CR.; Barbanoj, MJ.; Clotet, B.  Variability in non-nucleoside reverse transcriptase and protease inhibitors concentrations among HIV-infected adults in routine clinical practice.
2007	Clin Exp Immunol 147:189-96
Pauls E, Senserrich J, Bofill M, Clotet B, Este JA.   Induction of interleukins IL-6 and IL-8 by siRNA.
2007	Clin Pharmacokinetic; 46 (1): 85-92. (IF: 4.115)
Moltó, J.; Valle, M.; Blanco, A.; Negredo, E.; Delavarga, M.; Miranda, C.; Miranda, J.; Domingo, P.; Vilaró, J.; Tural, C.; Costa, J.; Barbanoj, MJ.; Clotet, B.  Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co.infected patients without liver function impairment: influence of liver fibrosis.
2007	Curr Opin HIV AIDS; 2: 145-149.
Clotet, B.; Paredes, R.  Clinical approach to drug resistance interpretation: expert advice.
2007	Enfermedades infecciosas y Microbiol Clin; 25: 131-142.
Ribera, E.; Moreno, S.; Viciana, P.; Echevarria, S.; Flores, J.; Francés, A. et al y participantes en el documento (entre ellos JM Llibre)  Recomendaciones españolas sobre el uso adecuado de enfuvirtida.
2007	Enfermedades infecciosas y Microbiología Clínica; 25 (2): 98-107
Llibre, JM.; Casado, MA.; Sanchez de la Rosa, R.; Perez-Elias, MJ.; Santos, JR.; Miralles, C.; Martinez, E.; Domingo, P.; Alvarez, ML.; Moreno, S.  Costes de la toxicidad asociada a los análogos de nucleósidos inhibidores de la transcriptasa inversa en pacientes con infección por el VIH-1.
2007	Hepatitis Hoy; 3 (3):86-90
Tural, C.; Jou, A.; Sirera, G.; Salas, A.; Planas, R.; Clotet, B.  ¿Es diferente la cinética del virus de la Hepatitis C en los pacientes infectados por el virus de la inmunodeficiencia humana?
2007	Hepatology. (IF: 10.446)
Nattermann, J.; Vogel, M.; Berg, T.; Danta, M.; Axel, B.; Mayr, C.; Bruno, R.; Tural, C.; Klausen, G.; Clotet, B.; Lutz, T.; Grunhage, F.; Rausch, M.; Nischalke, HD.; Schewe, K.; Bienek, B.; Haerter, G.; Sauerbruch, T.; Rockstroh, JK.; Spengler, U.  Effect of the interleukin-6 C174G gene polymorphism on treatment of acute and chronic hepatitis C in human immunodeficiency virus coinfected patients.
2007	Hepatology; 45 (4): 899-910. (IF: 10.446).
Franco, S.; Parera, M.; Aparicio, E.; Clotet, B.; Martinez, MA.  Genetic and catalytic efficiency structure of an HCV protease quasispecies.
2007	HIV Clin Trials; 8 (4): 213-220. (IF: 1.704)
Rachlis, A.; Clotet, B.; Baxter, J.; Murphy, R.; Lefebvre, E.  Safety, tolerability and efficacy of Darunavir (TMC114) with low-dose Ritonavir in treatment-experienced, hepatitis B or C co-infected patients in POWER 1 and 3.
2007	HIV Med; 8 (8): 568-570 (IF: 1.934).
Llibre, JM.; Perez-Alvarez, N.  Methodological accuracy in cross-trial comparisons of antiretroviral regimens in multitreated patients.
2007	HIV Med; 8: 259-264. (IF: 1.934).
Llibre, JM.; Perez-Alvarez, N.; Hill, A.; Moyle, G.  Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
2007	J Acquir Immune Defic Syndr.; 45 (4): 479-481. (IF: 3.946)
Clotet, B.; Negredo, E.; Girard, PM.; Youle, M.; Neubacher, D.  Compromised immunologic recovery in patients receiving tipranavir/ritonavir coadministered with tenofovir and didanosine in randomised: Evaluation of Strategic Intervention in multidrug-resistant patients with tipranavir (RESIST) studies.
2007	J Antimicrob Chemother (en prensa)
Negredo, E.; Puigdomènech, I.; Marfil, S.; Puig, J.; Pérez-Álvarez, N.; Ruiz, L.; Rey-Joly, C.; Clotet, B.; Blanco, J.  Association between HIV replication and cholesterol in peripheral blood mononuclear cells in HIV-infected patients interrupting HAART.
2007	J Antimicrob Chemother; 60 (2): 436-439. (IF: 3.891)
Moltó, J.; Santos, JR.; Negredo, E.; Miranda, C.; Videla, S.; Clotet, B.  Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.
2007	J Hepatol; 47 (4): 447-450. (IF: 10.446).
Degos, F.; Tural, C.  Hepatocellular carcinoma in human immunodeficiency virus (HIV)-infected patients: is it really different, and if so, why?
2007	J Infect Dis.; 196 (2): 178-180. (IF: 5.363)
Clotet, B.  CCR5 inhibitors: promising yet challenging.
2007	J Leukoc Biol.; 82 (1): 72-78. (IF: 4.572)
De Arquer, GR.; Pena, R.; Cabrera, C.; Coma, G.; Ruiz-Hernández, R.; Guerola, R.; Clotet, B.; Ruiz, L.; Esté, JA.; Calle, LM.; Bofill, M.  Skewed expression and up-regulation of the IL-12 and IL-18 receptors in resting and activated CD4 T cells from HIV-1 infected patients.
2007	J Mass Spectrom.
Pruvost, A.; Théodoro, F.; Agrofolio, K.; Negredo, E.; Bénech. H.  Specificity enhancement with LC-positive ESI-MS/MS for the measurement of nucleotides: application to the quantitative determination of carbovir triphosphate and tenofovir diphosphate in human peripheral blood mononuclear cells.
2007	J Viral Hepat; 14 (10): 704-713. (IF: 3.29)
Tural, C.; Solà, R.; Rubio, R.; Santín, M.; Planas, R.; Quereda, C.; Berenguer, J.; Montes-Ramirez, M.; Clotet, B.; and the CORAL-1 study group.  Safety and efficacy of an induction dose of pegylated interferon alpha-2a on early hepatitis C virus kinetics in HIV/HCV co-infected patients: the CORAL-1 multicentre pilot study.
2007	J Virol Methods (IF: 2.097).
Paredes, R.; Marconi, VC.; Campbell, TB.; Kuritzkes, DR.  Systematic evaluation of allele-specific real-time PCR for the detection of minor HIV-1 variants with pol and env resistance mutations.
2007	J Virol. (IF: 5.341)
Villena, C.; Prado, JG.; Puertas, MC.; Martinez, MA.; Clotet, B.; Ruiz, L.; Parkin, MT.; Menendez-Arias, L.; Martinez-Picado, J.  Relative fitness and replication capacity of a multinucleoside analogue-resistant clinical HIV-1 isolate with a deletion of codon 69 in the reverse transcriptase.
2007	J Virol. (IF: 5.341).
Gimenez-Barcons, M.; Clotet, B.; Martinez, MA.  Endoribonuclease-prepared siRNAs induce effective and specific inhibition of HIV-1 replication.
2007	J Virol; 81 (14): 7559-7570. (IF: 5.341).
Izquierdo-Useros, N.; Blanco, J.; Erkizia, I.; Fernadez-Figueras, MT.; Borras, FE.; Naranjo-Gomez, M.; Bofill, M.; Ruiz, L.; Clotet, B.; Martinez-Picado, J.  Maturation of blood-derived dendritic cells enhaces human immunodeficiency virus type 1 capture and transmission.
2007	J Virol; 81 (5): 2485-2496. (IF: 5.341).
Fernandez, G.; Clotet, B.; Martinez, MA.  Fidness landscape of human immunodeficiency virus type 1 protease quasispecies.
2007	JAIDS; 44: 139-147
Podzamczer, D.; Ferrer, E.; Sanchez, P.; Gatell, JM.; Crespo, M.; Fisac, C.; Lonca, M.; Sanz, J.; Niubo, J.; Veloso, S.; Llibre, JM.; Barrufet, P.; Ribas, MA.; Merino, E.; Ribera, E.; Martínez-Lacasa, J.; Alonso, C.; Aranda, M.; Pulido, F.; Berenguer, J.; Delegido, A.; Pedreira, J.; Lérida, A.; Rubio, R.; Del Río, L. for the ABCDE Study Team.  Less lipoatrophy and better lipid profile with abacavir as compared to stavudine. 96-week results of a randomized study.
2007	Journal of Acquired Immune Deficiency Syndrome; 46: 253-255.
Ferrer, E.; Niubo, J.; Crespo, M.; Gatell, JM.; Sanz, J.; Veloso, S.; Llibre, JM.; Barrufet, P.; Sanchez, P.; Podzamczer, D. for the ABCDE Study Team.  Genotypic resistance in HIV-infected naïve patients receiving abacavir plus lamivudine and efavirenz.
2007	Journal of the International Neuropsychological Society; 13 (1): Supplement S1: 19
Muñoz-Moreno, JA.; Fumaz, CR.; Ferrer, MJ.; Ávila, R.; Prats, A.; Guillamon, N.; Negredo, E.; Garolera, M.; Clotet, B.   Benefits of a cognitive rehabilitation program on Neurocognitive Impairment in HIV-infected patients. Preliminary Findings.
2007	Lancet; 369 (9568): 1169-1178. (IF: 25.800).
Clotet, B.; Bellos, N.; Molina, JM.; Cooper, D.; Goffard, JC.; Lazzarin, A.; Wohrmann, A.; Katlama, C.; Wilkin, T.; Haubrich, R.; Cohen, C.; Farthing, C.; Jayaweera, D.; Markowitz, M.; Ruane, P.; Spinosa-Guzman, S.; Lefebvre, E.  Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
2007	Lancet; 370 (9581): 39-48. (IF: 25.800).
Lazzarin, A.; Campbell, T.; Clotet, B.; Johnson, M.; Katlama, C.; Moll, A.; Towner, W.; Trottier, B.; Peeters, M.; Vingerhoets, J.; de Smedt, G.; Baeten, B.; Beets, G.; Sinha, R.; Woodfall, B.  Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1 infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial.
2007	Leuk Lymphoma; 48: 2058-2059
Xicoy, B.; Ribera, JM.; Romeu, J.; Mate, JL.; Millà, F.; Feliu, E.  Response to highly active antiretroviral therapy as the only therapy in an HIV-infected patient with interfollicular Hodgkin's lymphoma.
2007	Med Clin; 129 (2): 70-76
Negredo, E.; Pagés, M.; Ramírez, J.  A 50-year-old male with AIDS and retroperitoneal mass.
2007	Med Clin; 129 (8): 309-313
Bruguera, M.; Torres, M.; Campins, M.; Bayas, JM.; Segura, A.; Barrio, JL.; Esteban, R.; Gatell, JM.; Martínez, M.; Monés, J.; Plans, A.; Planas, R.; Serra, C.; Tural, C.; Villalbí, JR.  Risk of transmition of HIV or hepatitis B or C viruses from an infected physician. Preventive measures.
2007	Mol Biol Evol; 24 (2): 382-327. (IF: 6.726)
Parera, M.; Fernandez, G.; Clotet, B.; Martinez, MA.  HIV-1 protease catalytic efficiency effects caused by random single amino acid substitutions.
2007	Nutr Hosp; 22 (2): 229-243.
Polo, R.; Gómez-Candela, C.; Miralles, C.; Locutura, J.; Álvarez, J.; Barreiro, F.; Bellido, D.; Câncer, E.; Cànoves, D.; Domingo, P.; Estrada, V.; Fumaz, CR.; Galindo, MJ.; García-Benayas, T.; Iglesias, C.; Irles, JA.; Jimenez-Nacher, I.; Lozano, F.; Marqués, I.; Martinez-Alvarez, JR.; Mellado, MJ.; Miján, A.; Ramos, JT.; Riobo, P.; SPNS/GEAM/SENBA/SENPE/AEDN/SEDCA/GESIDA.  Recommendations from SPNS/GEAM/SENBA/SENPE/AEDN/SEDCA/GESIDA on nutrition in the HIV-infected patient.
2007	Pharmacoeconomics-Spanish Research articles; 4 (1): 25-36
Moreno, S.; Casado, MA.; Domingo, P.; Llibre, JM.; Martínez, E.; Miralles, C.; Santos, J.; Pérez-Elías, MJ.; Herrera, S.; Sánchez de la Rosa, R.  Análisis de minimización de costes de diferentes combinaciones de inhibidores de la transcriptasa inversa análogos de nucleósidos asociados a acontecimientos adversos en pacientes infectados por el VIH-1.
2007	Sex Trans Dis; 34 (3): 141-144.
Libois, A.; de Wit, S.; Poll, B.; Garcia, F.; Florence, E.; Del Río, A.; Sanchez, P.; Negredo, E.; Vandenbruaene, M.; Gatell, JM.; Clumeck, N.  HIV and syphili: when to perform a lumbar puncture.
2007	Ther Drug Mon: 29 (5): 648-651
Moltó, J.; Santos, JR.; Valle, M.; Miranda, C.; Miranda, J.; Blanco, A.; Negredo, E.; Clotet, B.  Monitoring atazanavir concentrations with boosted or unboosted regimens in HIV-infected patients in routine clinical practice.
2007	Top HIV Med; 15 (4): 119-125.
Johnson, VA.; Brun-Bezinet, F.; Clotet, B.; Gunthard, HF.; Kuritzkes, DR.; Pillay, D.; Schapiro, JM.; Richman, DD.  Update of the Drug Resistance Mutations in HIV-1: 2007.
2007	Virus Res; 123 (2): 161-169. (IF: 2.783).
Franco, S.; Tural, C.; Clotet. B.; Martinez, MA.  Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients coinfected with human immunodeficiency virus Type 1.
2006	AIDS Res Hum Retroviruses , 22 (1): 33-39
S Lopez , E Negredo , G Garrabou , J Puig , L Ruiz , E Sanjurjo , X Ramos , AB Infante , J Casademont , F Cardellach, B Clotet , O Miro.  Longitudinal study on mitochondrial effects of didanosine-tenofovir combination
2006	AIDS Res Hum Retroviruses , 22 (5) : 393-400
R Sola , J A Galeras , S Montoliu , C Tural , L Force , S Torra , S Montull , E R Castro , S Coll , D Fuster , P Barrufet , G Sirera , M D Gimenez , B Clotet , R Planas  Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment.
2006	AIDS Res Hum Retroviruses, 22 (4): 321-329
A Bonjoch , R Paredes , P Domingo , M Cervantes , E Pedrol , E Ribera , L Force , J M Llibre , J Vilaro , D Dalmau , J Cucurull , J Mascaro , A Masabeu , N Perez-Alvarez , J Puig , D Cinguegrana , B Clotet  Long-term safety and efficacy of nevirapine-based approaches in HIV type 1-infected patients.
2006	AIDS Researh Human Retrovirus , 22 (9): 893-896
M Bofill , J Martinez-Picado , R Ruiz , C Cabrera , S Marfil , I Erkizia , R Bellido , J Romeu , B Clotet , L Ruiz  Naive CD4(+) T cells and recent thymic emigrant levels in treated individuals with HIV: clinical relevance.
2006	AIDS, 20 (14) : 1896-1898
A Bonjoch , E Negredo , J Puig , I Erkizia , T Puig , C Cabrera , L Ruiz , B Clotet  Viral failure in HIV-infected patients with long-lasting viral suppression who discontinued enfuvirtide.
2006	AIDS, 20 (16) : 2075-2080
C Cabrera, S Marfil , E Garcia , J Martinez-Picado , A Bonjoch , M Bofill , S Moreno , E Ribera , P Domingo , B Clotet , L Ruiz  Genetic evolution of gp41 reveals a highly exclusive relationship between codons 36, 38 and 43 in gp41 under long-term enfuvirtide-containing salvage regimen
2006	AIDS, 20 (8) : 1201-1204
G Sirera , S Videla , M Pinol , M P Canadas , M Llatjos , A L Ballesteros , F Garcia-Cuyas , E Castella , R Guerola , C Tural , C Rey-Joly , B Clotet  High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV-positive men.
2006	AIDS. 20:619-21.
Negredo E, Clotet B, Puig J, Perez-Alvarez N, Ruiz L, Romeu J, Molto J, Rey-Joly C, Blanco J.  The effect of atorvastatin treatment on HIV-1-infected patients interrupting antiretroviral therapy.
2006	Antimicrob Agents Chemother 49 (10) : 4296-4304
B Bosch , J Blanco , E Pauls , I Clotet-Codina , M Armand-Ugon , B Grigorov , D Muriaux , B Clotet , J L Darlix , J A Este   Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein
2006	Antiviral Res. 69:173-80.
Bosch B, Clotet-Codina I, Blanco J, Pauls E, Coma G, Cedeno S, Mitjans F, Llano A, Bofill M, Clotet B, Piulats J, Este JA.  Inhibition of human immunodeficiency virus type 1 infection in macrophages by an alpha-v integrin blocking antibody.
2006	Antiviral Ther , 11 (4) : 473-482
D Fuster , R Planas , J Gonzalez , L Force , M Cervantes , J Vilaro , M Roget , I Garcia , E Pedrol , J Tor , AL Ballesteros , A Salas , G Sirera , S Videla , B Clotet , C Tural.   Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response.
2006	Antiviral Therapy, 11: 47–51
J Moltó, L Ruiz, M Valle, J Martinez-Picado, A Bonjoch, I Bravo, E Negredo, G M Heilek-Sneider, B Clotet  Increased antiretroviral potency by the addition of enfuvirtide to a four-drug regimen in antiretroviralnaive, HIV-infected patients
2006	Bioorg Med Chem 14:6255-82
Lysek R, Schutz C, Favre S, O'Sullivan AC, Pillonel C, Krulle T, Jung PM, Clotet-Codina I, Este JA, Vogel P.   Search for alpha-glucosidase inhibitors: new N-substituted valienamine and conduramine F-1 derivatives.
2006	Bioorg Med Chem Lett. 16:3541-4
Mugnaini C, Manetti F, Este JA, Clotet-Codina I, Maga G, Cancio R, Botta M, Corelli F.  Synthesis and biological investigation of S-aryl-S-DABO derivatives as HIV-1 inhibitors.
2006	Br J Clin Pharmacol , 62 (5) : 560-566
J Molto, A Blanco , C Miranda , J Miranda , J Puig , M Valle , M Delavarga , CR Fumaz , M J Barbanoj , B Clotet .  Variability in non-nucleoside reverse transcriptase and protease inhibitor concentrations among HIV-infected adults in routine clinical practice.
2006	Clinical and Experimental Immunology 145:535–544
Coma G, Peña R, Blanco J, Rosell A, Borras FE, Esté JA, ClotetB, Ruiz L, Parkhouse RME and Bofill M  Treatment of monocytes with interleukin (IL)-12 plus IL-18 stimulates survival, differentiation and the production of CXC chemokine ligands (CXCL)8, CXCL9 and CXCL10
2006	Enferm Infecc Microbiol Clin , 24 (4): 219-221
C Cabrera , B Clotet  Resistance genotyping in patients with therapeutic failure
2006	HIV Clin Trials 7:86-96
Youle M, Staszweski S, Clotet B, Arribas JR, Blaxhult A, Carosi G, Dejesus E, Di Perri G, Estrada V, Fisher M, Kovacs C, Kulasegaram R, Lazzarin A, Marriott D, Munoz L, Reynes J, Shalit P, Slim J, Tsoukas C, Vaccaro A, Vera J.   Concomitant use of an active boosted protease inhibitor with enfuvirtide in treatment-experienced, HIV-infected individuals: recent data and consensus recommendations.
2006	HIV Med , 7 (2): 67-74
A Hill , S Walmsley , B Clotet , J Molto  Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir.
2006	J Antimicrob Chemother , 58 (2) : 235-242
E Negredo , A Bonjoch , B Clotet  Benefits and concerns of simplification strategies in HIV-infected patients
2006	J Antimicrob Chemother 58:235-42
Negredo E, Bonjoch A, Clotet B.   Benefits and concerns of simplification strategies in HIV-infected patients.
2006	J Chem Inf Model 46:1344-51
Manetti F, Tintori C, Armand-Ugon M, Clotet-Codina I, Massa S, Ragno R, Este JA, Botta M.   A combination of molecular dynamics and docking calculations to explore the binding mode of ADS-J1, a polyanionic compound endowed with anti-HIV-1 activity.
2006	J Gen Virol , 87 (Pt 5) : 1285-1294
G Fernandez , A Llano, M Esgleas , B Clotet , J A Este , MA Martinez  Purifying selection of CCR5-tropic human immunodeficiency virus type 1 variants in AIDS subjects that have developed syncytium-inducing, CXCR4-tropic viruses
2006	J Leukoc Biol , 80 (3) : 659-667
E Pauls , J Senserrich , B Clotet , J A Esté  Inhibition of HIV-1 replication by RNA interference of p53 expression
2006	J Virol. 80:3617-3623.
Martinez-Picado J, Prado JG, Fry EE, Pfafferott K, Leslie A, Chetty S, Thobakgale C, Honeyborne I, Crawford H, Matthews P, Pillay T, Rousseau C, Mullins JI, Brander C, Walker BD, Stuart DI, Kiepiela P, Goulder P.  Fitness Cost of Escape Mutations in p24 Gag in Association with Control of Human Immunodeficiency Virus Type 1.
2006	J. Exp. Med.. 203: 529-539.
Draenert R, Allen TM, Liu Y, Wrin T, Chappey C, Verrill CL, Sirera G, Eldridge RL, Lahaie MP, Ruiz L, Clotet B, Petropoulos CJ, Walker BD, Martinez-Picado J.   Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus.
2006	Journal of Infectious Diseases. 194: 38-91
Gumà M, Cabrera C, Erkizia I, Bofill M, Clotet B, Ruiz L and Lopez-Botet M  Human Cytomegalovirus Infection Is Associated with Increased Proportions of NK Cells That Express the CD94/NKG2C Receptor in Aviremic HIV-1–Positive Patients
2006	Mini Rev Med Chem 6:91-108
Pettersson S, Clotet-Codina I, Este JA, Borrell JI, Teixido J.   Recent advances in combinatorial chemistry applied to development of anti-HIV drugs.
2006	Top HIV Med 14:125-30
Johnson VA, Brun-Vezinet F, Clotet B, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD.   Update of the drug resistance mutations in HIV-1: Fall 2006.
2006	Virus Res
S Franco , C Tural , B Clotet , M A Martinez  Complete nucleotide sequence of genotype 4 hepatitis C viruses isolated from patients co-infected with human immunodeficiency virus type 1.
2005	AIDS 19: 2117-2125.
Mocroft A, Soriano V, Rockstroh J, Reiss P, Kirk O, de Wit S, Gatell J, Clotet B, Phillips AN, Lundgren JD; EuroSIDA Study Group.  Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?
2005	J Infect Dis , 192 (6) : 992-1002
J K Rockstroh , A Mocroft , V Soriano , C Tural , M H Losso , A Horban , O Kirk , A Phillips , B Ledergerber , J Lundgren , EuroSIDA Study Group  Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy
2005	J Virol , 80 (2) : 571-577
R Sabariegos , M Jiménez-Barcons , N Tapia , B Clotet , M A Martínez  Sequence homology required by human immunodeficiency virus type 1 to escape from short interfering RNAs.
2005	AIDS 19: 343-345
Negredo E, Martinez-Lopez E, Paredes R, Rosales J, Perez-Alvarez N, Holgado S, Gel S, del Rio L, Tena X, Rey-Joly C, Clotet B.  Reversal of HIV-1-associated osteoporosis with once-weekly alendronate.
2005	AIDS 19: 569-575
Barrios A, Rendon A, Negredo E, Barreiro P, Garcia-Benayas T, Labarga P, Santos J, Domingo P, Sanchez-Conde M, Maida I, Martin-Carbonero L, Nunez M, Blanco F, Clotet B, Sambeat MA, Gil P, Gonzalez-Lahoz J, Cooper D, Soriano V.  Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.
2005	AIDS 19:1697-1700.
Moncunill G, Negredo E, Bosch L, Vilarrasa J, Witvrouw M, Llano A, Clotet B, Este JA  Evaluation of the anti-HIV activity of statins.
2005	AIDS, 19 : 2117-2125
A Mocroft , V Soriano , J Rockstroh , P Reiss , O Kirk , S de Wit , J Gatell , B Clotet , A N Philips , J D Lundgren , for the EuroSIDA study group  Evidence for an increase in the death rate from liver-related disease in patients with HIV : Teh EuroSIDA study
2005	Antimicrob Agents Chemother, 49 (5) : 1907-1914
A Pruvost , E Negredo , H Benech , F Theodoro , J Puig , E Grau , E García , J Moltó , J Gras , B clotet  Measurement of intracellular didanosine and tenofovir phosphorylated metabolites and possible interaction of the two drugs in human immunodeficiency virus-infected patients.
2005	Antimicrob Agents Chemother. 49:3926-3929
Blanco J, Clotet-Codina I, Bosch B, Armand-Ugon M, Clotet B, Este JA  Multiparametric assay to screen and dissect the mode of action of anti-human immunodeficiency virus envelope drugs.
2005	Antimicrob Agents Chemother. 49:4296-304.
Bosch B, Blanco J, Pauls E, Clotet-Codina I, Armand-Ugon M, Grigorov B, Muriaux D, Clotet B, Darlix JL, Este JA  Inhibition of coreceptor-independent cell-to-cell human immunodeficiency virus type 1 transmission by a CD4-immunoglobulin G2 fusion protein.
2005	Antimicrobial Agents and Chemotherapy 49(5):1907-14
Pruvost A, Negredo E, Benech H, Theodoro F, Puig J, Grau E, Garcia E, Molto J, Grassi J, Clotet J  Measurement of Intracellular Didanosine and Tenofovir Phosphorylated Metabolites and Possible Interaction of the Two Drugs in Human Immunodeficiency Virus-Infected Patients
2005	Antiviral Therapy 10: 825-832.
Barrios A, Negredo E, Domingo P, Estrada V, Labarga P, Asensi V, Morales D, Santos J, Clotet B, Soriano V; EFADITE Study Group.  Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: final results of the EFADITE trial.
2005	Antiviral Therapy 10: 791-802.
Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy.  Cozzi-Lepri A, Ruiz L, Loveday C, Phillips AN, Clotet B, Reiss P, Ledergerber B, Holkmann C, Staszewski S, Lundgren JD; EuroSIDA Study Group.
2005	Antiviral Therapy 10: 841-847
Fuster D, Huertas JA, Gomez G, Sola R, Gonzalez Garcia J, Vilaro J, Pedrol E, Force L, Tor J, Sirera G, Videla S, Planas R, Clotet B, Tural C; PEG-TOX Research Group.   Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy.
2005	Clinical Infectious Diseases 40:1342–9
M Gimenez-Barcons, M Ribera, A Llano, B Clotet, JA Este, MA Martinez  Analysis of Chemokine and Cytokine Expression in Patients with HIV and GB Virus Type C Coinfection
2005	Clinical Infectious Diseases 41: 901-905
Negredo E, Bonjoch A, Paredes R, Puig J, Clotet B.  Compromised immunologic recovery in treatment-experienced patients with HIV infection receiving both tenofovir disoproxil fumarate and didanosine in the TORO studies.
2005	Clinical Infectious Diseases; 41:729–37
Prado JG, Parkin NT, Clotet B, Ruiz L, Martinez-Picado J  HIV Type 1 Fitness Evolution in Antiretroviral-Experienced Patients with Sustained CD4+ T Cell Counts but Persistent Virologic Failure
2005	Expert Opin Pharmacother. 6: 1565-1572.
Fuster D, Clotet B.   Review of atazanavir: a novel HIV protease inhibitor.
2005	HIV Med 6: 107-13
Johnson M, Nieto-Cisneros L, Horban A, Arasteh K, Gonzalez-Garcia J, Artigas J, Clotet B, Danise A, Landman R, Proll S, Snowden W, Foreman R, Smith P.  Comparison of gastrointestinal tolerability and patient preference for treatment with the 625 mg and 250 mg nelfinavir tablet formulations.
2005	Immunologia , 24 (2) : 246-260
A Llano , J A Esté  Cytokines, chemokines and their receptors as modulators of the replication and evolution of HIV-1
2005	Journal Antimicrob Chemother. 55: 824-827.
Ballesteros AL, Fuster D, Planas R, Clotet B, Tural C.   Role of viral kinetics under HCV therapy in HIV/HCV-coinfected patients
2005	Journal of Acquired Immune Deficiency Syndromes 38: 560-565
Fumaz CR, Munoz-Moreno JA, Molto J, Negredo E, Ferrer MJ, Sirera G, Perez-Alvarez N, Gomez G, Burger D, Clotet B.  Long-Term Neuropsychiatric Disorders on Efavirenz-Based Approaches: Quality of Life, Psychologic Issues, and Adherence.
2005	Journal of Acquired Immune Deficiency Syndromes 38: 47-52
Negredo E, Molto J, Burger D, Cote H, Miro O, Ribalta J, Martinez E, Puig J, Ruiz L, Salazar J, Lopez S, Montaner J, Rey-Joly C, Clotet B.  Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study).
2005	Journal of Acquired Immune Deficiency Syndromes 40: 413-421.
Trottier B, Walmsley S, Reynes J, Piliero P, O'Hearn M, Nelson M, Montaner J, Lazzarin A, Lalezari J, Katlama C, Henry K, Cooper D, Clotet B, Arasteh K, Delfraissy JF, Stellbrink HJ, Lange J, Kuritzkes D, Eron JJ Jr, Cohen C, Kinchelow T, Bertasso A, Labriola-Tompkins E, Shikhman A, Atkins B, Bourdeau L, Natale C, Hughes F, Chung J, Guimaraes D, Drobnes C, Bader-Weder S, Demasi R, Smiley L, Salgo MP.  Safety of enfuvirtide in combination with an optimized background of antiretrovirals in treatment-experienced HIV-1-infected adults over 48 weeks.
2005	Journal of Immunology, 174: 5655-5664
Colobran R., Adreani P, Ashhab Y., Llano A., Esté JA., Dominguez O., Pujol-Borrell R., Juan M.  Multiple products derived from two CCl4 loci: high incidence of a new polymorphism in HIV+ patients.
2005	Journal of Medicinal Chemistry 48: 8000-8008
Manetti F, Este JA, Clotet-Codina I, Armand-Ugon M, Maga G, Crespan E, Cancio R, Mugnaini C, Bernardini C, Togninelli A, Carmi C, Alongi M, Petricci E, Massa S, Corelli F, Botta M.  Parallel solution-phase and microwave-assisted synthesis of new S-DABO derivatives endowed with subnanomolar anti-HIV-1 activity.
2005	Journal of Acquired Immune Deficiency Syndromes 39: 313-316.
Bonjoch A, Paredes R, Galvez J, Miralles C, Videla S, Martinez E, Miranda J, Munoz-Moreno JA, De la Torre J, Prieto A, Vilades C, Clotet B; and the SimplifiHAART Study Group.  Antiretroviral treatment simplification with 3 NRTIs or 2 NRTIs plus nevirapine in HIV-1-infected patients treated with successful first-line HAART.
2005	Journal of Acquired Immune Deficiency Syndromes 40: 404-412
M Nelson, K Arasteh, B Clotet, DA Cooper, K Henry, C Katlama, JP Lalezary, A Lazzarin, J SG Montaner, M O’Hearn, PJ Piliero, J Reynes, B Trottier, S Walmsley, C Cohen, J Eron Jr, DS Kuritzkis, J Lange, HJ Stellbrink, JD Delfraissy.   Durable efficacy of enfuvirtide over 48 wks among demographic, baseline and treatment subgroups in the TORO 1 and TORO 2 clinical trials.
2005	Journal of Clinical Microbiology 43: 436–438
Martinez-Picado J, Morales-Lopetegi K, Villena C, Gutiérrez C, Izquierdo , Marfil S, Clotet B, Ruiz L  Evidence for Preferential Genotyping of a Minority Human Immunodeficiency Virus Population Due to Primer-Template Mismatching during PCR-Based Amplification
2005	Journal of Virology 79: 5907–13
J Martinez-Picado, T Wrin, SDW Frost, B Clotet, L Ruiz, AJ Leigh Brown, CJ Petropoulos, NT Parkin  Phenotypic Hypersusceptibility to Multiple Protease Inhibitors and Low Replicative Capacity in Patients Who Are Chronically Infected with Human Immunodeficiency Virus Type 1
2005	Med Clin , 124 (14) : 525-531
A Jaen , J Casabona , A Esteve , J M Miró , C Tural , E Ferrer , M Riera , F Segura , L Force , O Sued , J Vilaró , A Masabeu , I García , E Dorca , J Altés , G Navarro , D Podzamczer , C Villalonga , B Clotet , J M Gatell , Grupo de estudio Piscis  Características clinicopidemiológicas y tendencias en el tratamiento antiretroviral de un cohorte de pacientes con infección por el virus de la immunodeficiencia humana.
2005	Med Clin 124 (16) : 618 - 619
C Cabrera , B Clotet  Mutaciones de resistencia a agentes antiretrovirales en pacientes con infección por el VIH
2005	Med. Clin , 125 (4) : 127-131
G Sirera , S Videla , E Castella , L Cavallé , N Grané , M Llatjós , C Tural , E Negredo , A Fernández, C Rey-Joly , B Clotet  Contribución de la captura de híbridos de segunda generación del virus del papiloma humano en el cribado de afección cervical en mujeres con infección por el VIH
2005	Top HIV Med. 13: 51-57.
Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, Schapiro J, Telenti A, Richman D.  Update of the Drug Resistance Mutations in HIV-1: 2005.
2005	Topics in HIV Medicine 13:125-31
Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD.  Update of the drug resistance mutations in HIV-1: Fall 2005.
2005	Virology 343: 141-149
Armand-Ugon M, Clotet-Codina I, Tintori C, Manetti F, Clotet B, Botta M, Este JA  The anti-HIV activity of ADS-J1 targets the HIV-1 gp120.
2005	Virology. 338:1-8
Tapia N, Fernandez G, Parera M, Gomez-Mariano G, Clotet B, Quinones-Mateu M, Domingo E, Martinez MA  Combination of a mutagenic agent with a reverse transcriptase inhibitor results in systematic inhibition of HIV-1 infection
2004	Top HIV Med 12( 4 ): 119-124.
V A Johnson , F Brun-Vezinet , B Clotet , B Conway , R T D'Aquila , L M Demeter , D R Kuritzkes , D Pillay , J M Schapiro , A Telenti , D E Richman   Update of the drug resistance mutations in HIV-1: 2004
2004	AIDS 18 (12) : 1673-1682
J Barretina , J Blanco , A Bonjoch , A Llano , B Clotet , J A Este  Immunological and virological study of enfuvirtide-treated HIV-positive patients
2004	AIDS 18: ..59–66
Ballesteros A L, Franco S, Fuster D, Planas R, Martínez M A, Acosta L, Sirera G, Salas A, Tor J, Rey-Joly C, Clotet B, Tural C.  Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches
2004	AIDS 18: .459-463
Negredo E, Molto J, Burger D, Viciana P, Ribera E, Paredes R, Juan M, Ruiz L, Puig J, Pruvost A, Grassi J, Masmitja E, Clotet B.  Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load.
2004	AIDS 18: .819-21
Negredo E, Ribalta J, Ferre R, Salazar J, Rey-Joly C, Sirera G, Masana L, Clotet B.  Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients.
2004	AIDS 18: 1137-1146
Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: consensus recommendations.  Clotet B, Raffi F, Cooper D, Delfraissy JF, Lazzarin A, Moyle G, Rockstroh J, Soriano V, Schapiro J.
2004	AIDS 18: 1673-1682
Barretina J, Blanco J, Bonjoch A, Llano A, Clotet B, Este JA  Immunological and virological study of enfuvirtide-treated HIV-positive patients
2004	Aids Ciber Journal 7 (6)
J A Muñoz , C R Fumaz , A Prats , M J Ferrer , B Clotet  Evaluación de los déficit cognitivos en pacientes infectados por el VIH
2004	AIDS Research and Human Retroviruses 20: 1293-1297
Fuster D, Planas R, Muga R, Ballesteros AL, Santos J, Tor J, Sirera G, Guardiola H, Salas A, Cabre E, Ojanguren I, Barluenga E, Rey-Joly C, Clotet B, Tural C.  Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy.
2004	AIDS Research and Human Retroviruses 20: 1283–1288
J Moltó, L Ruiz, J Romeu, J Martinez-Picado, E Negredo,C Tural, G Sirera, B Clotet  Influence of Prior Structured Treatment Interruptions on the Length of Time without Antiretroviral Treatment in Chronically HIV-Infected Subjects
2004	AIDS Reviews 6: 123-30
Clotet B.  Strategies for overcoming resistance in HIV-1 infected patients receiving HAART.
2004	AIDS, 18 : 1-12
R Paredes , B Clotet  New antiretroviral drugs and approaches to HIV treatment
2004	Antimicrob Agents and Chemotherapy 48: 4256-4262
Ribera E, Lopez RM, Diaz M, Pou L, Ruiz L, Falco V, Crespo M, Azuaje C, Ruiz I, Ocana I, Clotet B, Pahissa A.  Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
2004	Antimicrob Agents Chemother. 48 (11 ): 4256 - 4262
E Ribera , R M López , M Diaz , L Pou , L Ruiz , V Falcó , M Crespo , C Azuaje , L Ruiz , I Ocaña , B Clotet , A Pahissa  Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults
2004	Antivir Ther 9: 787-800.
Cabrera C, Cozzi-Lepri A, Phillips AN, Loveday C, Kirk O, Ait-Khaled M, Reiss P, Kjaer J, Ledergerber B, Lundgren JD, Clotet B, Ruiz L; EuroSIDA Study Group.  Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
2004	Antivir Ther 9: 969-77
Ballesteros AL, Miro O, Lopez S, Fuster D, Videla S, Martinez E, Garrabou G, Salas A, Cote H, Tor J, Rey-Joly C, Planas R, Clotet B, Tural C.  Mitochondrial effects of a 24-week course of pegylated-interferon plus ribavirin in asymptomatic HCV/HIV co-infected patients on long-term treatment with didanosine, stavudine or both.
2004	Antiviral Therapy 9: 335-342
Negredo E, Molto J, Munoz-Moreno JA, Pedrol E, Ribera E, Viciana P, Galindos MJ, Miralles C, Burger D, Rodriguez Fumaz C, Puig J, Gel S, Rodriguez E, Videla S, Ruiz L, Clotet B.  Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
2004	Antiviral Therapy 9: 465-478
Brun-Vezinet F, Costagliola D, Khaled MA, Calvez V, Clavel F, Clotet B, Haubrich R, Kempf D, King M, Kuritzkes D, Lanier R, Miller M, Miller V, Phillips A, Pillay D, Schapiro J, Scott J, Shafer R, Zazzi M, Zolopa A, DeGruttola V.  Clinically validated genotype analysis: guiding principles and statistical concerns.
2004	Antiviral Therapy 9:889–893
E Negredo, R Paredes, J Peraire, E Pedrol, H Côté, S Gel, CR Fumaz, L Ruiz, V Abril, E Rodriguez de Castro, C Ochoa, J Martinez-Picado, J Montaner, C Rey-Joly, B Clotet on behalf of the Swatch Study Team  Alternation of antiretroviral drug regimens for HIV infection. Efficacy, safety and tolerability at week 96 of the Swatch Study
2004	Business Briefing : long term healthcare : 2-8
E Negredo , L Ruiz , R Paredes , D Fuster , J Molto , B Clotet  Management of antiretroviral drug resistance in HIV-1 infected patients
2004	Clin. Exp. Immunol. 138: 460-465
M Bofill, E Almirall, A McQuaid, R Peña, R Ruiz-Hernandez, M Naranjo, L Ruiz, B Clotet & FE Borras  Differential expression of the cytokine receptors for human interleukin (IL)-12 and IL-18 on lymphocytes of both CD45RA+ and CD45RO+ phenotype from tonsils, cord and adult peripheral blood
2004	Curr Pharm Des , 10 (15) : 1845-1860
L Menéndez-Arias, J A Esté  HIV-resistance to viral entry inhibitors
2004	Drug Discovery Today Technologies, 1 : 135-140
E Pauls , M A Martínez , B Clotet , J A Esté  RNA interference of HIV coreceptors
2004	Enferm Infecc Microbiol Clin 22: 564-642
Iribarren JA, Labarga P, Rubio R, Berenguer J, Miro JM, Antela A, Gonzalez J, Moreno S, Arrizabalaga J, Chamorro L, Clotet B, Gatell JM, Lopez-Aldeguer J, Martinez E, Polo R, Tuset M, Viciana P, Santamaria JM, Kindelan JM, Ribera E, Segura F; Grupo de Estudio de Sida; Consejo Asesor Clinico del Plan Nacional sobre el Sida del Ministerio de Sanidad y Consumo.  [Spanish GESIDA/Nacional AIDS Plan Recommendations for antiretroviral therapy in HIV-infected Adults (October 2004)]
2004	GM Entorno Hospitalario. Diciembre :10
A Bonjoch , E Negredo , B Clotet  Indicaciones actuales y perspectivas futuras para los pacientes VIH1+
2004	HIV Clin Trials 5: 33-9
Clotet B, Carmena J, Pulido F, Luque I, Rodriguez-Alcantara F; COL30494 Cohort Study Members.  Adherence, quality of life, and general satisfaction with co-formulated zidovudine, lamivudine, and abacavir on antiretroviral-experienced patients.
2004	Immunology. International Proceedings. Medimon : 25-28
M Bofill , R Peña , R Ruiz-Hernandez , M Naranjo , B Clotet , F E Borras  The Cytokine receptors for human IL-12 and IL-18 are preferentially expressed on effector memory lymphocytes
2004	J Acquir Immune Defic Syndr 38 (1) : 47-52
E Negredo , J Moltó , D Burger , H Cote , J Ribalta , O Miró , L Ruiz , J Puig , J Salazar , S Loopez , P Domingo , S Videla , B Clotet  Lopinavir/ritonavir plus nevirapine as a nucleoside-sparing approach in antiretroviral-experienced patients (NEKA study).
2004	J HIV Ther 9: 75-8.
Molto J, Clotet B.  Therapeutic drug monitoring of antiretroviral agents scenario.
2004	J Viral Hepat. 11: 2-17
Soriano V, Miro JM, Garcia-Samaniego J, Torre-Cisneros J, Nunez M, del Romero J, Martin-Carbonero L, Castilla J, Iribarren JA, Quereda C, Santin M, Gonzalez J, Arribas JR, Santos I, Hernandez-Quero J, Ortega E, Asensi V, del Pozo MA, Berenguer J, Tural C, Clotet B, Leal M, Mallolas J, Sanchez-Tapias JM, Moreno S, Gatell JM, Tellez MJ, Rubio R, Ledesma E, Domingo P, Barreiro P, Pedreira J, Romero M, Gonzalez-Lahoz J, Lissen E.  Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations.
2004	J. Clin. Microbiol. 42 (4): 1620-1625
J.G. Prado, A. Shintani, M. Bofill, B. Clotet, L. Ruiz, and J. Martinez-Picado  Lack of Longitudinal Intrapatient Correlation between p24 Antigenemia and Levels of Human Immunodeficiency Virus (HIV) Type 1 RNA in Patients with Chronic HIV Infection during Structured Treatment Interruptions
2004	Journal of Biological Chemistry 279: 24569-24577
Matamoros T, Franco S, Vázquez-Álvarez BM, Mas A, Martínez MA, Menéndez-Arias L.  Molecular determinants of multi-nucleoside analogue resistance in HIV-1 reverse transcriptases containing a dipeptide insertion in the fingers subdomain (Effect of mutations D67N and T215Y on removal of thimidine nucleotide analogues from blocked CKED DNA primers)
2004	Journal of Infectious Diseases 189: 1444-51
Parera M, Ibanez A, Clotet B, Martinez MA.  Lack of evidence for protease evolution in HIV-1-infected patients after 2 years of successful highly active antiretroviral therapy.
2004	Journal of Infectious Diseases; 189:1444–51
Parera, M., Ibáñez, A., Clotet, B., and Martinez, M. A.  Lack of Evidence for Protease Evolution in HIV-1–Infected Patients after 2 Years of Successful Highly Active Antiretroviral Therapy
2004	Journal of Leukocyte Biology 76:804-811
Blanco J, Barretina J, Clotet B, Esté JA.  R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism.
2004	Journal of Virology vol.78: 14057–14061
M Parera, B Clotet, and MA Martinez  Genetic Screen for Monitoring Severe Acute Respiratory Syndrome Coronavirus 3C-Like Protease
2004	Med Clin , 123 (12) : 460-462
C Tural , B Clotet  La era del tratamiento antiretroviral de gran actividad y de la coinfección por el VHC
2004	Med Clin 122: 696-697
Paredes R, Clotet B.  [Duration of antiretroviral combinations]
2004	Med Clin 123: 460-462
Tural C, Clotet B.  [The era of antiretroviral therapy... and the era of hepatitis C virus coinfection]
2004	N Engl J Med. 2004 350: 1053-4; author reply 1053-4
Clotet B.  Comparison of regimens as initial therapy for HIV.
2004	Top HIV Med 12: 119-24
Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD.  Update of the drug resistance mutations in HIV-1: 2004.
2004	Vaccine 22: 2966-73
Fernandez-Cruz E, Moreno S, Navarro J, Clotet B, Bouza E, Carbone J, Pena JM, Perez Molina J, Podzamczer D, Rubio R, Ocana I, Pulido F, Viciana P, Maradona JA, Blazquez R, Barros C, Quereda C, Rodriguez-Sainz C, Gil J, Abad ML, Diaz L, Canto C, Munoz MA, Ferrer E, Jou A, Sirera G, Diaz M, Lopez F, Gatell JM, Gonzalez-Lahoz J; STIR-2102 TEAM.  Therapeutic immunization with an inactivated HIV-1 Immunogen plus antiretrovirals versus antiretroviral therapy alone in asymptomatic HIV-infected subjects.
2004	Virology 325 (2) : 389-398
M DBobardt , M Armand-Ugon , Clotet I, Zhang , David G, Este JA, Gallay PA.   Effect of polyanion-resistance on HIV-1 infection.
2004	Virology 326: 103-112
Prado JG, Franco S, Matamoros T, Ruiz L, Clotet B, Menéndez-Arias L, Martínez MA, Martinez-Picado J  Relative replication fitness of multi-nucleoside analogue-resistant HIV-1 strains bearing a dipeptide insertion in the fingers subdomain of the reverse transcriptase and mutations at codons 67 and 215
2003	AIDS 17 Suppl 4: S85-96
Paredes R, Clotet B.  New antiretroviral drugs and approaches to HIV treatment.
2003	AIDS 17:1741-51
A Mocroft, L Ruiz, P Reiss, B Ledergerber, C Katlama, A Lazzarin, F-D Goebel, AN Phillips, B Clotet, JD Lundgren, for the EuroSIDA study group  Virological rebound after suppression on highly active antiretroviral therapy
2003	AIDS Cyber J , 6 : 2
D Fuster , A Ballesteros , G Sirera , A Salas , C Tural , B Clotet  Factores pronósticos de la hepatitis crónica VHC+ en pacientes VIH+
2003	AIDS Cyber J 6 (4) : 1-24
J M Gatell , B Clotet , D Podzamczer , J M Miró , J Mallolas , C Fortuny  Tratamiento antiretroviral en el año 2003 para adultos , adolescentes y niños
2003	AIDS Reviews 5: 19-24
Clotet B, Negredo E.   HIV protease inhibitors and dyslipidemia.
2003	Ann Hematol 82:500-505
Barretina, J., Junca, J., Llano, A., Gutierrez, A. Flores, A., Blanco, J., Clotet, B., Este, J. A.  CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease
2003	Ann Intern Med 139 (2) : 81-89.
L Ruiz , E Ribera , A Bonjoch , J Romeu , J Martinez-Picado , R Paredes , M Díaz , S Marfil , E Negredo , J García-Prado , C Tural , G Sirera , B Clotet  Role of a therapy interruption prior to 5-drug antiretroviral salvage regimen. The Retrogene Study
2003	Ann Intern Med 139:81-9.
J Martinez-Picado, E Negredo, L Ruiz, A Shintani, CR Fumaz, C Zala, P Domingo, J Vilaro, JM Llibre, P Viciana, K Hertogs, C Boucher, RT D’Aquila, B Clotet, and the SWATCH Study Team  Alternation of Antiretroviral Drug Regimens for HIV Infection: A Randomized, Controlled Trial
2003	Ann Intern Med. 15; 139(2) : 81-89.
J Martinez-Picado , E Negredo , L Ruiz , C R Fumaz , A Shintani , C Zala , P Domingo , J Vilaró , J M Llibre , P Viciana , K Hertogs, Ch Boucher , R D'Aquila , B Clotet , SWATCH study team  Alternation of antiretroviral drug regimens for HIV infection. A randomized, controlled trial
2003	Antimicrob Agents Chemother 47: 1760-5
Martinez, MA, and Clotet, B.  Genetic Screen for Monitoring Hepatitis C Virus NS3 Serine Protease Activity
2003	Antiv Res 59: 137-42
M Armand-Ugón, A Gutiérrez, B Clotet, JA Esté  HIV-1 resistance to the gp41-dependent fusion inhibitor C-34
2003	Antivir Ther 8: 1-8
Armand-Ugon M, Quinones-Mateu ME, Gutierez A, Barretina J, Blanco J, Schols D, De Clercq E, Clotet B, Este JA.  Reduced fitness of HIV-1 resistant to CXCR4 antagonists.
2003	Antivir Ther 8: 127-136
Cozzi-Lepri A, Phillips AN, Miller V, Katlama C, Ledergerber B, Vella S, Weber J, Bruun JN, Kirk O, Clotet B, Lundgrens JD.  Changes in viral load in people with virological failure who remain on the same HAART regimen.
2003	Antiviral Res 59 (2) : 137 - 142
M Armand-Ugon, A Gutierrez , B Clotet , J A Esté  HIV-1 resistance to the gp41-dependent fusion inhibitor C-34.
2003	Antiviral Ther , 8, 1 : 1-8
M Armand-Ugon , M E Quiñones-Mateu , A Gutierrez , J Blanco , D Sxhols , E De Clercq , B Clotet , J A Esté  Lower fitness of human immunodeficiency virus type 1 resistant to CXCR4 antagonists
2003	Antiviral Ther 8 : 91-100
A Cozzi-Lepri , A N Philips , V Miller , C Katlama , B Ledergerber , S Vella , J Weber , J N Bruun , O Kirk , B Clotet , J D Lundgren  Changes in viral load in people with virological failure who remain on the same HAART regimen
2003	Antiviral Ther 8:155-161
Barretina J, Blanco J, Armand-Ugon M, Gutierrez A, Clotet B, Este JA.  Anti-HIV-1 activity of enfuvirtide (T-20) by inhibition of bystander cell death.
2003	Arch Intern Med 163: 1220-1226
Fagard, C., Oxenius, A., Gunthard, H., Garcia, F., Le Braz, M., Mestre, G., Battegay, M., Furrer, H., Vernazza, P., Bernasconi, E., Telenti, A., Weber, R., Leduc, D., Yerly, S., Price, D., Dawson, S. J., Klimkait, T., Perneger, T. V., McLean, A., Clotet, B., Gatell, J. M., Perrin, L., Plana, M., Phillips, R., Hirschel, B.  A prospective trial of structured treatment interruptions in human immunodeficiency virus infection
2003	Clin Infect Dis 37(1) :113-128
M S Hirsch , F Brun-Vezinet , B Clotet , B Conway , D R Kuritzkes , R T D'Aquila , L M Demeter , S M Hammer , V A Johnson , C Loveday , J W Mellors , D MJacobsen , D D Richman   Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel
2003	Clin Infect Dis 37:113-28
MS Hirsch, F Brun-Vezinet, B Clotet, B Conway, DR Kuritzkes, RT D’Aquila, LM Demeter, SM Hammer, VA Johnson, C Loveday, JW Mellors, DM Jacobsen, DD Richman  Antiretroviral Drug Resistance Testing in Adults Infected with Human Immunodeficiency Virus Type 1: 2003 Recommendations of an International AIDS Society–USA Panel
2003	Clin Invest Arterioscl , 15 : 1 , 29-34
B Clotet , L Masana , J Pedro-Botet  Guía del manejo de las dislipemias en los pacientes infectados por el VIH: recomendaciones farmacológicas
2003	IAPAC Mon. 9: 145-165
Fumaz CR, Clotet B.  Assessment of changes in adherence and quality of life after the simplification of antiretroviral treatment.
2003	J Acquir Immune Defic Syndr 34 Suppl 1: S79-84
Clotet B, van der Valk M, Negredo E, Reiss P.  Impact of nevirapine on lipid metabolism.
2003	J Antimicrob Chemother 52: 464-8
Laguna, F., Videla, S., Jimenez-Mejias, M. E., Sirera, G., Torre-Cisneros, J., Ribera, E., Prados, D., Clotet, B., Sust, M., Lopez-Velez, R., Alvar, J., The Spanish, H. I. V. Leishmania Study Group  Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study
2003	J Gen Virol 84: 2217-28
J Weber, HR Rangel, B Chakraborty, M Tadele, MA Martinez, J Martinez-Picado, ML Marotta, M Mirza, L Ruiz, B Clotet, T Wrin, CJ Petropoulos, ME Quiñones-Mateu  A novel TaqMan real-time PCR assay to estimate ex vivo human immunodeficiency virus type 1 fitness in the era of multi-target (pol and env)antiretroviral therapy
2003	J Gen Virol 84: 607-13
Tapia N, Franco S, Puig-Basagoiti F, Menendez C, Alonso PL, Mshinda H, Clotet B, Saiz JC, Martinez MA.   Influence of human immunodeficiency virus type 1 subtype on mother-to-child transmission.
2003	J Infect Dis 188: 1827-33
Walmsley S, Henry K, Katlama C, Nelson M, Castagna A, Reynes J, Clotet B, Hui J, Salgo M, DeMasi R, Delehanty J.  Enfuvirtide (T-20) cross-reactive glycoprotein 41 antibody does not impair the efficacy or safety of enfuvirtide.
2003	J Infect Dis 188: 977-85
Ruiz L, Ribera E, Bonjoch A, Romeu J, Martinez-Picado J, Paredes R, Diaz M, Marfil S, Negredo E, Garcia-Prado J, Tural C, Sirera G, Clotet B.  Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study.
2003	J Int Assoc Physicians AIDS Care (Chic Ill). 2003 Apr-Jun;2(2): 56-8.
D Fuster , B Clotet  Chronic HCV infection in HIV-positive patients: A new challenge
2003	J Postgrad Med , 49 : 39-49
R Paredes , J Muñoz , I Diaz , P Domingo , M Guigui , B Clotet  Leishmaniasis in HIV Infection
2003	J Postgrad Med 49: 39-49
Paredes, R., Munoz, J., Diaz, I., Domingo, P., Gurgui, M., Clotet, B.  Leishmaniasis in HIV infection
2003	J Viral Hepat 10: 118-125
Tural C, Fuster D, Tor J, Ojanguren I, Sirera G, Ballesteros A, Lasanta JA, Planas R, Rey-Joly C, Clotet B.   Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients.
2003	J Virol 77: 4389-4395
Llano A, Barretina J, Gutierrez A, Clotet B, Este JA.  Interleukin-7-dependent production of RANTES that correlates with human immunodeficiency virus disease progression.
2003	JIAPAC , 9 : 145-165
C R Fumaz , B Clotet  Assessment of changes in adherence and quality of life after the simplification of antiretroviral treatment
2003	N Engl J Med , 348 : 2186-2195
A Lazzarin , B clotet , D Cooper , J Reynes , K Arastej , M Nelson , C Katlama , H J Setllbrink , J F Delfraissy , J Lange , L Huson , R DeMasi , C Wat , J Delehanty , C Drobnes , M Salgo ,   Enfuvirtide combined with an antiretroviral optimised background (OB) regimen in highly experienced HIV-1 patients: week 24 efficacy results of a Phase III randomized trial in Europe and Australia
2003	N Engl J Med 348:2186-95
A Lazzarin, B Clotet, D Cooper,J Reynes, K Arastéh, M Nelson, C Katlama, H-J. Stellbrink, J-F. Delfraissy, J. Lange, L. Huson, R. DeMasi, C. Wat, J. Delehanty, C. Drobnes, M. Salgo, for the TORO 2 Study Group  Efficacy of Enfuvirtide in Patients Infected with Drug-Resistant HIV-1 in Europe and Australia
2003	The Journal of Infectious Diseases, 188:977-85
L Ruiz, E Ribera, A Bonjoch, J Romeu, J Martinez-Picado, R Paredes, M Diaz, S Marfil, E Negredo, J Garcia-Prado, C Tural, G Sirera, and B Clotet  Role of Structured Treatment Interruption before a 5-Drug Salvage Antiretroviral Regimen: The Retrogene Study
2003	Top HIV Med 11: 150-154
Hirsch, M. S., Brun-Vezinet, F., Clotet, B., Conway, B., Kuritzkes, D. R., D'Aquila, R. T., Demeter, L. M., Hammer, S. M., Johnson, V. A., Loveday, C., Mellors, J. W., Richman, D. D.  Questions to and Answers from the International AIDS Society-USA Resistance Testing Guidelines Panel
2003	Top HIV Med 11: 215-21
Johnson VA, Brun-Vezinet F, Clotet B, Conway B, D'Aquila RT, Demeter LM, Kuritzkes DR, Pillay D, Schapiro JM, Telenti A, Richman DD; International AIDS Society-USA Drug Resistance Mutations Group.  Drug resistance mutations in HIV-1.
2003	Topics in HIV Medicine 11: 92-96
D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD.  Drug resistance mutations in HIV-1
2003	Topics in HIV Medicine 11 (6): 215-221
V A Johnson , F Brunt-Vezinet , B Clotet , B Conway , R D'Aquila , L Demeter , D Kuritzkes , D Pilay , J Schapiro , A Telenti , D Richman  Drug Resistance mutations in HIV-1
2003	VIH: I+T 8 ; 1 : 12
B Clotet  Experiencias en rescate, "naive" y simplificación
2003	Virology 305:318-329
Blanco J, Barretina J, Ferri KF, Jacotot E, Gutierrez A, Armand-Ugon M, Cabrera C, Kroemer G, Clotet B, Este JA.   Cell-surface-expressed HIV-1 envelope induces the death of CD4 T cells during GP41-mediated hemifusion-like events.
2002	AIDS , 16: 1 - 9
J García-Prado , T Wrin , J Beauchaine , L Ruiz , C J Petropoulos , B Clotet , R D'Aquila , J Martínez-Picado  Amprenavir resistant mutants show reduced viral fitness and cross-resistance to lopinavir
2002	AIDS 16 (12) : 1663-1671
A Mocroft , R Brettle , O Kirk , A Blaxhult , J M Parkin , F Antunes , P Francioli , A D'Arminio Monforte , Z Fox , J D Lundgren , EuroSIDA study group  Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study
2002	AIDS 16: 1009-1017
Prado JG, Wrin T, Beauchaine J, Ruiz L, Petropoulos CJ, Frost SDW, Clotet B, D'Aquila RT and Martinez-Picado J  Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity
2002	AIDS 16: 1383-1389
Negredo E, Ribalta J, Paredes R, Ferre R, Sirera G, Ruiz L, Salazar J, Reiss P, Masana L, Clotet B.   Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine.
2002	AIDS 16:209-218
Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, Domingo P, Boucher C, Rey-Joly C, Clotet B, and the Havana Study Group  Clinical utility of HIV-1 genotyping and expert advice: the Havana trial
2002	AIDS 16:2385-2390.
Martinez MA, Gutierrez A, Armand-Ugon M, Blanco J, Parera M, Gomez J, Clotet B, Este JA.  Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication.
2002	AIDS 16:895-899
Martinez-Picado J, Morales-Lopetegi K, Wrin T, Prado JG, Frost S, Petropoulos CJ, Clotet B and Ruiz L  Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions
2002	AIDS Res Hum Retroviruses 18:27-38
Blanco J, Barretina J, Gutierrez A, Armand-Ugon M, Cabrera C, Clotet B, and Esté JA  Preferential Attachment of HIV Particles to Activated and CD45RO+CD4+ T Cells
2002	AIDS Rev 4:36-40
Paredes R, Lopez Benaldo de Quiros JC, Fernandez-Cruz E, Clotet B, Lane HC.   The potential role of interleukin-2 in patients with HIV infection.
2002	Antivir Ther 7:21-30
Mocroft A, Phillips AN, Friis-Moller N, Colebunders R, Johnson AM, Hirschel B, Saint-Marc T, Staub T, Clotet B, Lundgren JD; EuroSIDA study group.   Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study.
2002	Antiviral Res 53: 1-8
Cabrera, C., Gutierrez, A., Barretina, J., Blanco, J., Litovchick, A., Lapidot, A., Clotet, B., Este, J. A.  Anti-HIV activity of a novel aminoglycoside-arginine conjugate
2002	Butlletí del medicament , 4 : 19
N Rudi , X Bonafont , J Costa , P Salva , C Tural , B Clotet , C Rodrigo  Recomanacions per a evitar interaccions amb els antiretrovirals
2002	Clin Infect Dis 34:504-10
Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression.   Negredo E, Cruz L, Paredes R, Ruiz L, Fumaz CR, Bonjoch A, Gel S, Tuldra A, Balague M, Johnston S, Arno A, Jou A, Tural C, Sirera G, Romeu J, Clotet B.
2002	Enferm Infecc Microbiol Clin 20 (6): 244-303
R Rubio , J Berenguer , J M Miró , A Antela , J A Iribarren , J Gonzalez , S Moreno , J Arrizabalaga , B Clotet , J M Gatell , F Laguna , E Martínez , F Parras , J M Santamaría , M Tuset , P Viciana por el GESIDA , el CAC del Plan Navional sobre el SIDA del Ministerio de Sanidad y Consumo  Recomendaciones del GESIDA/Plan Nacional sobre el SIDA respecto al tratamiento antiretroviral en pacientes adultos infectados por el virus de la inmunodeficiencia humana en el año 2002
2002	Enferm Infecc Microbiol Clin 20 Suppl 2:68-73.
Garcia F, Clotet B, Moreno S, Lopez Bernaldo De Quiros JC, Gatell JM.   Treatment interruptions in clinical practice
2002	Enferm Infecc Microbiol Clin 20: 244-303
Rubio R, Berenguer J, Miro JM, Antela A, Iribarren JA, Gonzalez J, Guerra L, Moreno S, Arrizabalaga J, Clotet B, Gatell JM, Laguna F, Martinez E, Parras F, Santamaria JM, Tuset M, Viciana P.   [Spanish GESIDA/National AIDS Plan Recommendations for Antiretroviral Therapy in HIV-infected Adults in the year 2002]
2002	Epidemiol Infect 129:325-33.
Egea JM, Muga R, Sirera G, Clotet B, Tor J, Ardevol M, Rey-Joly C, Munoz A.   Initiation, changes in use and effectiveness of highly active anti-retroviral therapy in a cohort of injecting drug users.
2002	HIV Clin Trials 2002;3(4):316-323
B Clotet, L Ruiz, J Martinez-Picado, E Negredo, A Hill, M Popescu  Prevalence of HIV Protease Mutations on Failure of Nelfinavir-Containing HAART: A Retrospective Analysis of Four Clinical Studies and Two Observational Cohorts
2002	Int J Infect Dis 6:17-22
Pedro-Botet ML, Modol JM, Valles X, Romeu J, Sopena N, Gimenez M, Tor J, Clotet B, Sabria M.   Changes in bloodstream infections in HIV-positive patients in a university hospital in Spain (1995-1997).
2002	J Acquir Immune Defic Syndr 29:244-253
Fumaz CR, Tuldra A, Ferrer MJ, Paredes R, Bonjoch A, Jou T, Negredo Romeu J, Sirera G, Tural C, and Clotet B.  Quality of Life, Emotional Status, and Adherence of HIV-1–Infected Patients Treated With Efavirenz Versus Protease Inhibitor–Containing Regimens
2002	J Clin Microbiol 40:3865-6.
Gallego O, Ruiz L, Vallejo A, Clotet B, Leal M, Soriano V.  Rate of Virological Treatment Failure and Frequencies of Drug Resistance Genotypes among Human Immunodeficiency Virus-Positive Subjects on Antiretroviral Therapy in Spain.
2002	J Infect Dis 186:189-97
Miller V, Phillips AN, Clotet B, Mocroft A, Ledergerber B, Kirk O, Ormaasen V, Gargalianos-Kakolyris P, Vella S, Lundgren JD.   Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts.
2002	J Virol 76: 968-979
Frost SDW, Martinez-Picado J, Ruiz L, Clotet B, and Leigh Brown AJ  Viral Dynamics during Structured Treatment Interruptions of Chronic Human Immunodeficiency Virus Type 1 Infection
2002	J Virol 76:10546-10552
ME Quinones-Mateu,M Tadele, M Parera, A Mas, J Weber,HR Rangel, B Chakraborty, B Clotet, E Domingo, L Menendez-Arias, MA Martinez  Insertions in the Reverse Transcriptase Increase both Drug Resistance and Viral Fitness in a Human Immunodeficiency Virus Type 1 Isolate Harboring the Multi-Nucleoside Reverse Transcriptase Inhibitor Resistance 69 Insertion Complex Mutation
2002	J Virol 76:12344-12348
J Martinez-Picado, SDW Frost, N Izquierdo, K Morales-Lopetegi, S Marfil, T Puig, C Cabrera, B Clotet, L Ruiz  Viral Evolution during Structured Treatment Interruptions in Chronically Human Immunodeficiency Virus-Infected Individuals
2002	Top HIV Med 10: 21-25
D'Aquila RT, Schapiro JM, Brun-Vezinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD; International AIDS Society-USA.  Drug Resistance Mutations in HIV-1.
2002	Topics in HIV Medicine 10 (2) : 11-15
R D'Aquila , J M Schapiro , F Brun-Vézinet , B Clotet , B Conway , L Demeter , R Grant , V A Johnson , D Kuritkes , C Loveday , R Shafer , D D Richman  Drug Resistance mutations in HIV-1
2002	Trends Immunol 23: 559-561
Martínez MA, Clotet B and Esté JA  RNA interference of HIV replication
2002	Virology 300:71-8
Cabana M, Fernandez G, Parera M, Clotet B, Martinez MA.  Catalytic efficiency and phenotype of HIV-1 proteases encoding single critical resistance substitutions.
2002	Virology, 300 : 71-78
M Cabana , G Fernandez , M Parera , B Clotet , M A Martínez  Proteolytic efficiency and drug susceptibility of HIV-1 proteases carrying single critical substitutions in the development of PI resistances
2001	AIDS 25, 15 (8) : 999 - 1008
O Kirk , A Mocroft , C Pradier , J N Bruun , R Hemmer , B Clotet , V Miller , J P Viard , A Philips , J D Lundgren , for the EuroSIDA study group.   Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir.
2001	AIDS , 15 : 2407-2414
M Van der Valk , J J Kastelein , R L Murphy , F Van Leth , C Katlama , A Horban , M Glesby , G Behrens , B Clotet , R K Stellato , H Molhuizen , P Reiss on behalf of the Atlantic Study Team  Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an antiatherogenic lipid profile
2001	AIDS 15 ; 15 (9) : F19 -27
L Ruiz , G Carcelain , J Martínez-Picado , S Frost , S Marfil , R Paredes , J Romeu , E Ferrer , K Morales-Lopetegi , M K Zayat , B Autran , B Clotet  HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection.
2001	AIDS 15: 1890-1892 [Research letter]
Llano, A., Barretina, J., Blanco, J., Gutierrez, A., Clotet, B., and Este, J. A.  Stromal-cell-derived factor 1 prevents the emergence of the syncytium- inducing phenotype of HIV-1 in vivo.
2001	AIDS 15: 1894-1896 [Research letter]
Gallego, O., Ruiz, L., Vallejo, A., Ferrer, E., Rubio, A., Clotet, B., Leal, M., and Soriano, V.:   Changes in the rate of genotypic resistance to antiretroviral drugs in Spain
2001	AIDS 15: 1904-1906 [Research letter]
Tuldra, A., Fumaz, C. R., Ferrer, M. J., Paredes, R., Romeu, J., Ruiz, L., Bayes, R., and Clotet, B.:   Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads.
2001	AIDS 15: 2407-14
van der Valk M, Kastelein JJ, Murphy RL, van Leth F, Katlama C, Horban A, Glesby M, Behrens G, Clotet B, Stellato RK, Molhuizen HO, Reiss P; Atlantic Study Team.  Nevirapine-containing antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile.
2001	AIDS 15: 999-1008.
Kirk, O., Mocroft, A., Pradier, C., Bruun, J. N., Hemmer, R., Clotet, B., Miller, V., Viard, J. P., Phillips, A. N., and Lundgren, J. D.  Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir.
2001	AIDS 15: F19-27
Ruiz, L., Carcelain, G., Martinez-Picado, J., Frost, S., Marfil, S., Paredes, R., Romeu, J., Ferrer, E., Morales-Lopetegi, K., Autran, B., and Clotet, B  HIV dynamics and T-cell immunity after three structured treatment interruptions in chronic HIV-1 infection.
2001	AIDS 26; 15 (2): 201-209
A Mocroft , A N Phillips , V Miller , J Gatell , J van Lunzen , J M Parkin , R Weber , B Roge , A Lazzarin , J D Lundgren , EuroSIDA study group   The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.
2001	AIDS 28; 15 (14) : 1890-1892
A Llano , J Barretina , J Blanco , A Gutierrez , B Clotet , J A Esté  Stromal-cell-derived factor 1 prevents the emergence of the syncytium-inducing phenotype of HIV-1 in vivo.
2001	AIDS 28;15(14): 1890-1892
A Llano , J Barretina , J Blanco , A Gutierrez , B Clotet , J A Esté  Stromal-cell-derived factor 1 prevents the emergence of the syncytium-inducing phenotype of HIV-1 in vivo
2001	AIDS 5 ; 15 (1): 23-31
M Jouan , M Saves , R Tubiana , G Carcelain , N Cassoux , C Aubron-Olivier , A M fillet , M Nciri , B Senechal , C Tural , S Lasry , B Autran , C Katlama, for the RESTIMOP study team.  Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy
2001	Antivir Ther 6 (1) : 21-39
A M Vandamme , F Houyez , D Banhegyi , B Clotet , G de Schrijver , K de Smet , WW Hall , R Harrigan , N Hellmann , K Hertogs , C Holtzer , B Larder , D Pillay , E Race , J C Schmit , R Schuurman , E Shulse , A Sonnerborg , V Miller  Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up
2001	Antivir Ther 6: 21-39.
Vandamme, A. M., Houyez, F., Banhegyi, D., Clotet, B., De Schrijver, G., De Smet, K. A., Hall, W. W., Harrigan, R., Hellmann, N., Hertogs, K., Holtzer, C., Larder, B., Pillay, D., Race, E., Schmit, J. C., Schuurman, R., Schulse, E., Sonnerborg, A., and Miller, V.  Laboratory guidelines for the practical use of HIV drug resistance tests in patient follow-up.
2001	Enferm Infecc Microbiol Clin 19 : 34-41
B Clotet , J Martínez-Picado , J Arrizabalaga , L Ruiz  Resistance to protease inhibitors
2001	Enferm Infecc Microbiol Clin 19: 34-41.
Clotet, B., Martinez-Picado, J., Arrizabalaga, J., and Ruiz, L.:   Resistance to protease inhibitors
2001	Enferm Infecc Microbiol Clin 19: 47-52.
Antela, A., Iribarren, J. A., Clotet, B., and Guerra, L.  Consensus documents and clinical guidelines on resistance to antiretroviral agents
2001	Enferm Infecc Microbiol Clin 19: 53-60.
Gatell, J. M., Blanco, J. L., Alcami, J., Antela, A., Arrizabalaga, J., Casado, J. L., Clotet, B., Delgado, R., Erice, A., Guerra, L., Guerrero, A., Iribarren, J. A., Leal, M., Lopez, J. C., Menendez-Arias, L., Miro, J. M., Moreno, S., Perez, J. L., Pumarola, T., Rubio, R., Ruiz, L., Santamaria, J. M., Soriano, V., Telenti, A., and Viciana, P.  GESIDA Consensus document on the use of resistance studies in clinical practice
2001	HIV Med. 2:27-34.
Katlama C, Clotet B, Plettenberg A, Jost J, Arasteh K, Bernasconi E, Jeantils V, Cutrell A, Stone C, Purdon S; CNA3002 European Study Team.  Intensification of stable background therapy with abacavir in antiretroviral therapy experienced patients: 48-week data from a randomized, double-blind trial.
2001	Intervirology 44 (6): 339-343
C Briones , A Mas , M Pérez-Olmesa , L Ruiz , B Clotet  Prevalence and genetic heterogeneity of the reverse transcriptase T69S-S-X insertion in pretreated HIV-infected patients
2001	J Acquir Immune Defic Syndr 27: 229-236.
Ruiz, L., Negredo, E., Domingo, P., Paredes, R., Francia, E., Balague, M., Gel, S., Bonjoch, A., Fumaz, C. R., Johnston, S., Romeu, J., Lange, J., and Clotet, B.  Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1- year prospective follow-up of a multicenter, randomized, controlled study.
2001	J Med Virol 63: 85-87
Perez-Olmeda, M., Del Romero, J., Rubio, A., Ruiz, L., Rodriguez, C., Leal, M., Clotet, B., and Soriano, V.  Primary HIV-1 drug resistance in Spain before and after the introduction of protease inhibitors.
2001	J Rheumatol 28 (4) : 802-804
E Casado , A Olivé , S Holgado , R Perez-Andrés , J Romeu, J C Lorenzo , B Clotet , X Tena  Musculoskeletal manifestations in patients positive for human immunodeficiency virus: correlation with CD4 count.
2001	J Rheumatol 28: 802-804
Casado, E., Olive, A., Holgado, S., Perez-Andres, R., Romeu, J., Lorenzo, J. C., Clotet, B., and Tena, X.  Musculoskeletal manifestations in patients positive for human immunodeficiency virus: correlation with CD4 count.
2001	J Virol 75: 10319-10325.
Llano, A., Barretina, J., Gutierrez, A., Blanco, J., Cabrera, C., Clotet, B., and Este, J. A.:  Interleukin-7 in plasma correlates with CD4 T-cell depletion and may be associated with emergence of syncytium-inducing variants in human immunodeficiency virus type 1-positive individuals.
2001	Revista de la Reial Acacèmia de Medicina de Catalunya vol.16 , num.3
B Clotet  Reptes de la SIDA en el nou mil·leni
2001	Virology 282: 1-5
Ibanez, A., Clotet, B., and Martinez, M. A.  Absence of genetic diversity reduction in the HIV-1 integrated proviral LTR sequence population during successful combination therapy.
2001	Virology 285: 356-365
Blanco, J., Barretina, J., Cabrera, C., Gutierrez, A., Clotet, B., and Este, J. A.  CD4+ and CD8+ T cell death during human immunodeficiency virus infection in vitro.
2000	AIDS 10 ; 14 (4) : 397 -403
L Ruiz , J Martínez-Picado , J Romeu , R Paredes , E Negredo , C Tural , B Clotet  Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.
2000	AIDS 10; 14 (16): 2485-2494
F García , H Knobel , M A Sambeat , J Arrizabalaga , M Aranda , J Romeu , D Dalmau , F Segura , J L Gómez-Sirvent , E Ferrer , A Cruceta , T Gallart , T Pumarola , J M Miró , J M Gatell , Spanish Scan Study Group  Comparison of twice-daily stavudine plus once- or twice-daily didanosine and nevirapine in early stages of HIV infection: the scan study.
2000	AIDS 14: 2857-2867.
Miller, V., Sabin, C., Hertogs, K., Bloor, S., Martinez-Picado, J., D'Aquila, R., Larder, B., Lutz, T., Gute, P., Weidmann, E., Rabenau, H., Phillips, A., and Staszewski, S.:   Virological and immunological effects of treatment interruptions in HIV- 1 infected patients with treatment failure.
2000	AIDS 14: 397-403.
L Ruiz , J Martínez-Picado, J Romeu , R Paredes , M K Zayat , S Marfil , E Negredo , G Sirera , C Tural , B Clotet   Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression.
2000	AIDS 14: 469-471.
Van Laethem, K., Witvrouw, M., Balzarini, J., Schmit, J. C., Sprecher, S., Hermans, P., Leal, M., Harrer, T., Ruiz, L., Clotet, B., Van Ranst, M., Desmyter, J., De Clercq, E., and Vandamme, A. M.:   Patient HIV-1 strains carrying the multiple nucleoside resistance mutations are cross-resistant to abacavir.
2000	AIDS 14: 727-732.
Puig, T., Perez-Olmeda, M., Rubio, A., Ruiz, L., Briones, C., Franco, J. M., Gomez-Cano, M., Stuyver, L., Zamora, L., Alvarez, C., Leal, M., Clotet, B., and Soriano, V.:   Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. The ERASE-2 Study Group.
2000	AIDS 14: 781-789.
Katlama, C., Clotet, B., Plettenberg, A., Jost, J., Arasteh, K., Bernasconi, E., Jeantils, V., Cutrell, A., Stone, C., Ait-Khaled, M., and Purdon, S.:   The role of abacavir (ABC, 1592) in antiretroviral therapy-experienced patients: results from a randomized, double-blind, trial. CNA3002 European Study Team.
2000	AIDS 14: F1-7.
Casado, J. L., Hertogs, K., Ruiz, L., Dronda, F., Van Cauwenberge, A., Arno, A., Garcia-Arata, I., Bloor, S., Bonjoch, A., Blazquez, J., Clotet, B., and Larder, B.:   Non-nucleoside reverse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regimen.
2000	AIDS Res Hum Retroviruses 10; 16 (9) : 825 - 833
K Van Laethem , J C Schmit , H Pelemans , J Balzarini , M Witvrouw , M J Perez-Perez ,M J Camarasa , R M Esnouf , S Aquaro , A Cenci , C F Perno , P Hermans , S Sprecher , L Ruiz , B Clotet , Van Wijngaerden , Van Ranst , J Desmyter , E De Clercq , A M Vandamme   Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.
2000	AIDS Res Hum Retroviruses 16: 529-537.
Van Vaerenbergh, K., Van Laethem, K., Van Wijngaerden, E., Schmit, J. C., Schneider, F., Ruiz, L., Clotet, B., Verhofstede, C., Van Wanzeele, F., Muyldermans, G., Simons, P., Stuyver, L., Hermans, P., Evans, C., De Clercq, E., Desmyter, J., and Vandamme, A. M.:   Baseline HIV type 1 genotypic resistance to a newly added nucleoside analog is predictive of virologic failure of the new therapy.
2000	AIDS Res Hum Retroviruses 16: 627-634.
Cabrera, C., Gutierrez, A., Blanco, J., Barretina, J., Litovchick, A., Lapidot, A., Evdokimov, A. G., Clotet, B., and Este, J. A.:   Anti-human immunodeficiency virus activity of novel aminoglycoside- arginine conjugates at early stages of infection.
2000	AIDS Res Hum Retroviruses 16: 825-833.
Van Laethem, K., Schmit, J. C., Pelemans, H., Balzarini, J., Witvrouw, M., Perez-Perez, M. J., Camarasa, M. J., Esnouf, R. M., Aquaro, S., Cenci, A., Perno, C. F., Hermans, P., Sprecher, S., Ruiz, L., Clotet, B., Van Wijngaerden, E., Van Ranst, M., Desmyter, J., De Clercq, E., and Vandamme, A. M.:   Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino- 1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO- inexperienced HIV patients.
2000	AM J Respir Crit Care Med : 162 : 865-872
O Kirk , J M Gatell , A Mocroft , C Pedersen , R Proenca , R P Brettle , S E Barton , P Sudre , A N Philips , J D Lundgren , for the EuroSIDA study group ( J gonzalez-Lahoz and R Polo , B Clotet , A Jou , C Tural , J Gatell , J Miró  Infections with Mycobacterium Tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy
2000	Antimicrob Agents Chemother , 44 (5) : 1132-1139
MA Martínez , M Cabana , M Parera , A Gutierrez , J A Esté , B Clotet   A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 protease.
2000	Antimicrob Agents Chemother 44: 1132-1139.
Martinez, M. A., Cabana, M., Parera, M., Gutierrez, A., Este, J. A., and Clotet, B.:   A bacteriophage lambda-based genetic screen for characterization of the activity and phenotype of the human immunodeficiency virus type 1 protease.
2000	Antimicrob Agents Chemother 44: 2109-2117.
Van Vaerenbergh, K., Van Laethem, K., Albert, J., Boucher, C. A., Clotet, B., Floridia, M., Gerstoft, J., Hejdeman, B., Nielsen, C., Pannecouque, C., Perrin, L., Pirillo, M. F., Ruiz, L., Schmit, J. C., Schneider, F., Schoolmeester, A., Schuurman, R., Stellbrink, H. J., Stuyver, L., Van Lunzen, J., Van Remoortel, B., Van Wijngaerden, E., Vella, S., Witvrouw, M., Yerly, S., De Clercq, E., Destmyer, J., and Vandamme, A. M.:   Prevalence and characteristics of multinucleoside-resistant human immunodeficiency virus type 1 among European patients receiving combinations of nucleoside analogues.
2000	Antimicrob Agents Chemother 44: 51-56.
Blanco, J., Barretina, J., Henson, G., Bridger, G., De Clercq, E., Clotet, B., and Este, J. A.:   The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface- expressed human immunodeficiency virus type 1 envelope-induced apoptosis.
2000	Antivir Ther 5: 107-112.
Mocroft, A., Miller, V., Chiesi, A., Blaxhult, A., Katlama, C., Clotet, B., Barton, S., and Lundgren, J. D.:   Virological failure among patients on HAART from across Europe: results from the EuroSIDA study.
2000	Antiviral Res 46: 157-170.
Gimenez-Barcons, M., Sanchez-Fueyo, A., Ampurdanes, S., Puig-Basagoiti, F., Guilera, M., Ibanez, A., Clotet, B., Martinez, M. A., Rodes, J., Saiz, J. C., and Sanchez-Tapias, J. M.:   Genetic evolution of GB virus C/hepatitis G virus (GBV-C/HGV) under interferon pressure.
2000	Arch Intern Med 160: 1123-1132.
Paredes, R., Mocroft, A., Kirk, O., Lazzarin, A., Barton, S. E., van Lunzen, J., Katzenstein, T. L., Antunes, F., Lundgren, J. D., and Clotet, B.:   Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.
2000	Arch Intern Med 24 , 160 (8) : 1123 - 1132
R Paredes , A Mocroft , O Kitk , A Lazzarin , S E Barton , J van Lunzen , T L Katzenstein , F Antunes , J D Lundgren , B Clotet , for the EuroSida Study group  Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study
2000	Arch Intern Med 24 , 160 (8) : 1123-1132
R Paredes , A Mocroft , O kitk , A Lazzarin , S E Barton , J van Lunzen , T L Katzenstein , F Antunes , J D Lundgren , B Clotet , for the EuroSIDA Study group  Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from the EuroSIDA study.
2000	Enferm Infecc Microbiol Clin 18: 329-351.
Miro, J. M., Antela, A., Arrizabalaga, J., Clotet, B., Gatell, J. M., Guerra, L., Iribarren, J. A., Laguna, F., Moreno, S., Parras, F., Rubio, R., Santamaria, J. M., and Viciana, P.:   [Recommendation of GESIDA (AIDS Study Group)/National Plan on AIDS with respect to the anti-retroviral treatment in adult patients infected with the human immunodeficiency virus in the year 2000 (I)].
2000	Enferm Infecc Microbiol Clin 18: 396-412
Miro, J. M., Antela, A., Arrizabalaga, J., Clotet, B., Gatell, J. M., Guerra, L., Antonio Iribarren, J., Laguna, F., Moreno, S., Parras, F., Rubio, R., Santamaria, J. M., and Viciana, P.:   [Recommendations of GESIDA (Grupo de Estudio de SIDA)/National Plan on AIDS with respect to the anti-retroviral treatment in adult patients infected with the human immunodeficiency virus in the year 2000 (II)].
2000	Enfermedades Infeccioasa y Microbiología Clínica 18; 8 : 396-412
J M Miró , A Antela , J Arrizabalaga , B Clotet , J M Gatell , L Guerra , J A Iribarren , F Laguna , S Moreno , F Parras , R Rubio , J M Santamaría , P Viciana por el grupo GESIDA  Recomendaciones de GESIDA/Plan Nacional sobre el SIDA respecto al tratamiento antirretrovírico en pacientes adultos infectados por el virus de la immunodeficiencia humana en el siglo 2000 (II)
2000	Enfermedades Infecciosas y Microbiología Clínica , 18 ; 7 : 329-351
J M Miró , A Antela , J Arrizabalaga , B Clotet , J M Gatell , L Guerra , J A Irribarren , F Laguna , S Moreno , F Parras , R Rubio , J M Santamaría , P Viciana por el grupo GESIDA  Recomendaciones de GESIDA/Plan Nacional sobre el SIDA respecto el tratamiento antirretrovirico en pacientes adultos infectados por el virus de la immunodeficiencia humana en el siglo 2000
2000	J Acquir Immune Defic Syndr 23: 89-94.
Puig-Basagoiti, F., Cabana, M., Guilera, M., Gimenez-Barcons, M., Sirera, G., Tural, C., Clotet, B., Sanchez-Tapias, J. M., Rodes, J., Saiz, J. C., and Martinez, M. A.:   Prevalence and route of transmission of infection with a novel DNA virus (TTV), hepatitis C virus, and hepatitis G virus in patients infected with HIV.
2000	J Acquir Immune Defic Syndr 25: 221-228.
Tuldra, A., Fumaz, C. R., Ferrer, M. J., Bayes, R., Arno, A., Balague, M., Bonjoch, A., Jou, A., Negredo, E., Paredes, R., Ruiz, L., Romeu, J., Sirera, G., Tural, C., Burger, D., and Clotet, B.:   Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy.
2000	J Acquir Immune Defic Syndr 25: 26-35.
Garcia, F., Alonso, M. M., Romeu, J., Knobel, H., Arrizabalaga, J., Ferrer, E., Dalmau, D., Ruiz, I., Vidal, F., Frances, A., Segura, F., Gomez-Sirvent, J. L., Cruceta, A., Clotet, B., Pumarola, T., Gallart, T., O'Brien, W. A., Miro, J. M., and Gatell, J. M.:   Comparison of immunologic restoration and virologic response in plasma, tonsillar tissue, and cerebrospinal fluid in HIV-1-infected patients treated with double versus triple antiretroviral therapy in very early stages: The Spanish EARTH-2 Study. Early Anti-Retroviral Therapy Study.
2000	J Gen Virol 81 Pt 1: 85-95.
Ibanez, A., Clotet, B., and Martinez, M. A.:   Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies.
2000	J of HIV Therapy 5 :3 ; 64-66
R Paredes , L Ruiz  Changing from a protease inhibitor to a non-nucleoside reverse transcriptase inhibitor
2000	JAMA 283: 2417-2426.
Hirsch, M. S., Brun-Vezinet, F., D'Aquila, R. T., Hammer, S. M., Johnson, V. A., Kuritzkes, D. R., Loveday, C., Mellors, J. W., Clotet, B., Conway, B., Demeter, L. M., Vella, S., Jacobsen, D. M., and Richman, D. D.  Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA Panel.
2000	JANO Medicina y Humanidades , 13
J Martínez-Picado, B Clotet  Tratamiento de la infección por VIH: más allá de la carga viral
2000	JEM 192; 8 : 1-13
K F Ferry , E Jacotot , J Blanco , J A Esté , N Zamzami , S A Susuin , Z Xie , G Brothers , J Reed , J Penniger , G Kroemer  Apoptosis control in syncytia induced by the HIV type 1-envelope glycoprotein complex: role of Mitochondria and Caspases
2000	Rev Epidém et Santé Publ 48: 17-30
F Saillour-Glénisson , G Chene , L R Salmi , R Hafner , R Salamon et le groupe méta-analyse dapsone (G siera , B Clotet )   Effet de la dapsone sur la survie des patients infectés par le VIH : una méta-analyse des essais terminés
2000	Transfusion 40: 461-467.
Barretina, J., Blanco, J., Gutierrez, A., Puig, L., Altisent, C., Espanol, T., Caragol, I., Clotet, B., and Este, J. A.:   Evaluation of the putative role of C-C chemokines as protective factors of HIV-1 infection in seronegative hemophiliacs exposed to contaminated hemoderivatives.
1999	AIDS 13: 1045-1049.
Ibanez, A., Puig, T., Elias, J., Clotet, B., Ruiz, L., and Martinez, M. A.:   Quantification of integrated and total HIV-1 DNA after long-term highly active antiretroviral therapy in HIV-1-infected patients.
1999	AIDS 13: 1491-1496.
Garcia, F., Niebla, G., Romeu, J., Vidal, C., Plana, M., Ortega, M., Ruiz, L., Gallart, T., Clotet, B., Miro, J. M., Pumarola, T., and Gatell, J. M.:   Cerebrospinal fluid HIV-1 RNA levels in asymptomatic patients with early stage chronic HIV-1 infection: support for the hypothesis of local virus replication.
1999	AIDS 13: 1497-1502
J L Casado , J Arrizabalaga , M Montes , P Martí-Belda , C Tural , J Pinilla , C Gutierrez, J Portu , R Schuurman , K Aguirrebengoa for the CMV-AIDS Study Group  Incidence and risk factors for developing cytomegalovirus retinitis in HIV-infected patients receiving protease inhibitor therapy
1999	AIDS 13: 2377-2388.
Garcia, F., Romeu, J., Grau, I., Sambeat, M. A., Dalmau, D., Knobel, H., Gomez-Sirvent, J. L., Arrizabalaga, J., Cruceta, A., Clotet, B. G., Podzamczer, D., Pumarola, T., Gallart, T., O'Brien, W. A., Miro, J. M., and Gatell, J. M.:   A randomized study comparing triple versus double antiretroviral therapy or no treatment in HIV-1-infected patients in very early stage disease: the Spanish Earth-1 study.
1999	AIDS 13: 547-555.
Blanco, J., Cabrera, C., Jou, A., Ruiz, L., Clotet, B., and Este, J. A.:   Chemokine and chemokine receptor expression after combined anti-HIV-1 interleukin-2 therapy.
1999	AIDS 13: 909-917.
J Blanco , E Jacotot , C Cabrera , A Cardona , B Clotet, E De Clercq , J A Esté   The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling.
1999	AIDS 13: F1-8.
Ruiz, L., van Lunzen, J., Arno, A., Stellbrink, H. J., Schneider, C., Rull, M., Castella, E., Ojanguren, I., Richman, D. D., Clotet, B., Tenner-Racz, K., and Racz, P.:   Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue.
1999	AIDS Cyber Journal , 2 : 5
J A Esté , B Clotet  The HIV Coreceptors
1999	AIDS Cyber Journal , 2 : 674-681
M A Martínez , B Clotet  Clinical implications of the HIV-1 genetic variability
1999	AIDS Research and Human Retroviruses 15: 1535-1543.
Cabrera C, Witvrouw M, Gutierrez A, Clotet B, Kuipers ME, Swart PJ, Meijer DK, Desmyter J, De Clercq E, Este JA.   Resistance of the human immunodeficiency virus to the inhibitory action of negatively charged albumins on virus binding to CD4.
1999	Annals Internal Medicine , 130: 570-577
V Miller , A Mocroft , P Reiss , C Katlama , A Papadopoulos , T Katzenstein , J Van Lunzen , F Antunes , A Philips , J D Lundgren for the EuroSIDA Study Group. ( J Gonzalez-Lahoz and R Polo (Instituto Carlos III), B Clotet , A Jou , C Tural , J Gatell , J Miró  Relations among CD4 lymphocyte count Nadir , antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA Study
1999	Antivir Ther 4: 45- 49.
Rubio, A., Gomez-Cano, M., Puig, T., Leal, M., Perez-Olmeda, M., Ruiz, L., Clotet, B., Rey, C., Zamora, L., Xaus, N., and Soriano, V.:   Presence of genotypic resistance in nucleoside analogue-treated HIV-1- infected patients with undetectable viral load.
1999	Antivir Ther 4: 123-124.
M Gomez-Cano, A Rubio, L Ruiz , M Perez-Olmeda , M Leal , B Clotet , V Soriano   Efficiency of drug resistance genotypic tests in specimens with low HIV viral load.
1999	Antivir Ther 4: 179-181
Perez-Olmeda M, Rubio A, Puig T, Gomez-Cano M, Ruiz L, Leal M, Clotet B, Soriano V.  Evolution of genotypic resistance to nucleoside analogues in patients receiving protease inhibitor-containing regimens.
1999	Arch Intern Med 159: 1376-1377.
Tuldra, A., Ferrer, M. J., Fumaz, C. R., Bayes, R., Paredes, R., Burger, D. M., and Clotet, B.:   Monitoring adherence to HIV therapy.
1999	Int J Clin Pract Suppl 103: 21-25.
Clotet, B.:   Efavirenz: resistance and cross-resistance.
1999	J Acquir Immune Defic Syndr 22: 132-138.
Paredes, R., Puig, T., Arno, A., Negredo, E., Balague, M., Bonjoch, A., Jou, A., Tuldra, A., Tural, C., Sirera, G., Veny, A., Romeu, J., Ruiz, L., and Clotet, B.:   High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response.
1999	J Infect Dis 180: 56-60.
Arno, A., Ruiz, L., Juan, M., Jou, A., Balague, M., Zayat, M. K., Marfil, S., Martinez-Picado, J., Martinez, M. A., Romeu, J., Pujol-Borrell, R., Lane, C., and Clotet, B.:   Efficacy of low-dose subcutaneous interleukin-2 to treat advanced human immunodeficiency virus type 1 in persons with <=250/microL CD4 T cells and undetectable plasma virus load.
1999	J Med Virol 59: 480-490.
Cabana, M., Clotet, B., and Martinez, M. A.:   Emergence and genetic evolution of HIV-1 variants with mutations conferring resistance to multiple reverse transcriptase and protease inhibitors.
1999	J Virol 73: 5577-5585.
Este, J. A., Cabrera, C., Blanco, J., Gutierrez, A., Bridger, G., Henson, G., Clotet, B., Schols, D., and De Clercq, E.:   Shift of clinical human immunodeficiency virus type 1 isolates from X4 to R5 and prevention of emergence of the syncytium-inducing phenotype by blockade of CXCR4.
1999	JAIDS
F Puig , M Cabana , M Guilera , M Gimenez , G Sirera , C Tural , B Clotet , J Sánchez , J Rodés , J C Saiz , M A Martínez  Prevalence and route of Transmission of infection with a novel DNA virus (TTV) and Hepatitis G virus in patients infected with HIV
1999	JAMA
M Hirsch , B Vezinet , R D'Aquila , S Hammer , Johnson , Kuritzkes , Loveday , Mellors , B Clotet , B Conway , Demeter , S Vella , D Richman  Antiretroviral drug resistance testing in adult HIV-1 infection : Recommendations of an International AIDS Society - USA Panel
1999	JANO LVI, 1291 : 1028
B Clotet , R Paredes  Tratamiento del Sida y profilaxis de las infecciones asociadas en el año 2000
1999	Journal of virology , 73 , 7 : 5577-5585
J A Esté , C Cabrera , D Schols , J Blanco , A Gutierrez , G Bridger , G Henson , B Clotet , E De Clercq  Shift of X4 to R5 HIV from clinical isolates through blockade of the CXCR4 receptor by the bicyclam AMD3100
1999	Mol Pharmacol 55 : 67-73.
J A Esté , C Cabrera , E De Clercq , S Struyf , J Van Damme , G Bridger , R T Skerlj , M J Abrams, G Henson , A Gutierrez , B Clotet , D Schols   Activity of different bicyclam derivatives against human immunodeficiency virus depends on their interaction with the CXCR4 chemokine receptor.
1999	Scand J Infect Dis 31(1) : 37-42.
J Romeu , M Balague , L Ruiz , S Marfil , J M Gatell , T Puig , A Arno , C Tural , G Sirera , B Clotet   Short-term risk for AIDS-indicator diseases predicted by plasma HIV-1 RNA and CD4+ lymphocytes.
1999	The Lancet , 353 : 1293-1298
G J Weverling , A Mocroft , B Ledergerber , O Kirk , H Gonzales-Lahoz , A D'Arminio Monforte , R Proenca , A N Philips , J D Lundgren , P Reiss , for the EuroSIDA study group. (J Gonzalez-Lahoz and R Polo (Instituto Carlos III) B Clotet , A Jou , C Tural (Hospital Germans Trias i Pujol ) J Gatell and J Miró (Hospital Clinic de Barcelona) on behalf of Spanish centers  Discontinuation of Pneumocystis carinii pneumonia prophylaxis after the initiation of highly active antiretroviral therapy in HIV infection
1999	Transfusion, 40 (4) : 461 - 467
J Barretina , J Blanco , Ll Puig , C Altisent , T Español , I Caragol , B Clotet , J A Esté  Evaluation of the putative role of C-C chemokines as protective factors of HIV-1 infection in seronegative hemophiliacs exposed to contaminated hemoderivatives.
1999	Virology, 256 : 180-187.
M A Martínez , M Cabana , A Ibanez , B Clotet , A Arno , L Ruiz  Human immunodeficiency virus type 1 genetic evolution in patients with prolonged suppression of plasma viremia.
1999	Weekly highlights, 15 : 42 - 45
J A Esté  Retrovirus infections and antiviral research
1998	AIDS 12: 1015-1020.
Gomez-Cano, M., Rubio, A., Puig, T., Perez-Olmeda, M., Ruiz, L., Soriano, V., Pineda, J. A., Zamora, L., Xaus, N., Clotet, B., and Leal, M.:   Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain.
1998	AIDS 12: 1285-1289.
Vidal C, Garcia F, Romeu J, Ruiz L, Miro JM, Cruceta A, Soriano A, Pumarola T, Clotet B, Gatell JM.   Lack of evidence of a stable viral load set-point in early stage asymptomatic patients with chronic HIV-1 infection.
1998	AIDS 12: 2007-2015.
Schmit JC, Van Laethem K, Ruiz L, Hermans P, Sprecher S, Sonnerborg A, Leal M, Harrer T, Clotet B, Arendt V, Lissen E, Witvrouw M, Desmyter J, De Clercq E, Vandamme AM.   Multiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries.
1998	AIDS 12: 697-704.
Arno, A., Ruiz, L., Juan, M., Zayat, M. K., Puig, T., Balague, M., Romeu, J., Pujol, R., O'Brien, W. A., and Clotet, B.:   Impact on the immune system of undetectable plasma HIV-1 RNA for more than 2 years.
1998	Ann Rheum Dis, 57: 749.
Olive, A., Salavert, A., Manriquez, M., Clotet, B., and Moragas, A.:   Parotid lipomatosis in HIV positive patients: a new clinical disorder associated with protease inhibitors.
1998	Clin Infect Dis 26: 1368-1373.
Phillips, P., De Beule, K., Frechette, G., Tchamouroff, S., Vandercam, B., Weitner, L., Hoepelman, A., Stingl, G., and Clotet, B.:   A double-blind comparison of itraconazole oral solution and fluconazole capsules for the treatment of oropharyngeal candidiasis in patients with AIDS.
1998	Enferm Infecc Microbiol Clin 16: 374-376.
Moreno, S., Arrizabalaga, J., Gatell, J. M., Clotet, B., Aguirrebengoa, K., Antela, A., Iribarren, J. A., Laguna, F., Miro, J. M., Ocana, I., Rubio, R., Viciana, P., and Podzamczer, D.:   [Recommendations for antiretroviral treatment in 1998. AIDS Working Group of the Spanish Society for Infectious Diseases and Clinical Microbiology (SEIMC)].
1998	J Gen Virol
M Giménez-Barcons , A Sánchez-Fueyo , S Ampurdanés , F Puig , M Guilera , A Ibañez , B Clotet , M A Martínez , J Rodés , J C Saiz , J M Sánchez  Genetic evolution of hepatitis G virus/ GB virus C (HGV/GBV-C) under interferon pressure
1998	J Infect Dis 177: 1080-1083.
Tural, C., Romeu, J., Sirera, G., Andreu, D., Conejero, M., Ruiz, S., Jou, A., Bonjoch, A., Ruiz, L., Arno, A., and Clotet, B.:   Long-lasting remission of cytomegalovirus retinitis without maintenance therapy in human immunodeficiency virus-infected patients.
1998	J Int Assoc Physicians AIDS Care 4: 60-63.
Este, J. A. and Clotet, B.:   HIV phenotype & genotype data highlights Lake Maggiore meeting.
1998	J Med Virol 55: 293-299.
Ibanez, A., Gimenez-Barcons, M., Tajahuerce, A., Tural, C., Sirera, G., Clotet, B., Sanchez-Tapias, J. M., Rodes, J., Martinez, M. A., and Saiz, J. C.:   Prevalence and genotypes of GB virus C/hepatitis G virus (GBV-C/HGV) and hepatitis C virus among patients infected with human immunodeficiency virus: evidence of GBV-C/HGV sexual transmission.
1998	J Virol Methods 73: 77-82.
Schmit, J. C., Ruiz, L., Stuyver, L., Van Laethem, K., Vanderlinden, I., Puig, T., Rossau, R., Desmyter, J., De Clercq, E., Clotet, B., and Vandamme, A. M.:   Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations.
1998	JAMA 279: 1984-1991.
Hirsch, M. S., Conway, B., D'Aquila, R. T., Johnson, V. A., Brun-Vezinet, F., Clotet, B., Demeter, L. M., Hammer, S. M., Jacobsen, D. M., Kuritzkes, D. R., Loveday, C., Mellors, J. W., Vella, S., and Richman, D. D.:   Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel.
1998	Journal of Acquired Immune Deficiciency Syndromes 17: 239-244.
Phillips, A. N., Katlama, C., Barton, S., Vella, S., Blaxhult, A., Clotet, B., Goebel, F. D., Hirschel, B., Pedersen, C., and Lundgren, J. D.:   Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group.
1998	Journal of Acquired Immune Deficiciency Syndromes 19: 19-28.
Ruiz, L., Nijhuis, M., Boucher, C., Puig, T., Bonjoch, A., Martinez-Picado, J., Marfil, S., de Jong, D., Burger, D., Arno, A., Balague, M., and Clotet, B.:   Efficacy of adding indinavir to previous reverse transcriptase nucleoside analogues in relation to genotypic and phenotypic resistance development in advanced HIV-1-infected patients.
1998	Journal of Acquired Immune Deficiciency Syndromes 19: 55-60.
Vidal C, Garcia F, Gatell JM, Leal M, Clotet B, Pumarola T, Miro JM, Mallolas J, Ruiz L, Cruceta A, Tortajada C.   Predictive factors influencing peak viral load drop in response to nucleoside reverse transcriptase inhibitors in antiretroviral-naive HIV- 1-infected patients.
1998	Med Clin 110: 109-116.
Moreno, S., Arrizabalaga, J., Gatell, J. M., Clotet, B., Aguirrebengoa, K., Antela, A., Iribarren, J. A., Laguna, F., Miro, J. M., Ocana, I., Rubio, R., Viciana, P., and Podzamczer, D.:   [Recommendations on antiretroviral treatment. The AIDS Study Group of the Spanish Society of Infectious Diseases and Clinical Microbiology].
1998	Med Clin 110: 761-767.
Romeu, J., Balague, M., Ruiz, L., Marfil, S., Puig, T., Arno, A., Veny, A., Tural, C., Sirera, G., and Clotet, B.:   [Value of HIV-1 viral load and CD4 lymphocyte count as determinants of progression to AIDS and survival].